Broad diversity of human gut bacteria accessible via a traceable strain deposition
system

Thomas C. A. Hitch[1], Johannes M. Masson[1,#], Charlie Pauvert[1,#], Johanna Bosch[1],
Selina Nüchtern[1], Nicole Treichel[1], Marko Baloh[1], Soheila Razavi[1], Afrizal Afrizal[1],
Ntana Kousetzi[1], Andrea M. Aguirre[1], David Wylensek[1], Amy Coates[1], Susan A. V.
Jennings[1], Atscharah Panyot[1], Alina Viehof[1], Matthias A. Schmitz[1], Maximilian
Stuhrmann[1], Evelyn C. Deis[1], Kevin Bisdorf[1], Thorsten Cramer[2], Artur Lissin[3], Isabel
Schober[3], Julius Witte[3], Thomas Riedel[3], Marie Wende[4], Katrin A. Winter[4], Alessandra
Riva[5,6], Stefanie Trinh[7], Laura Mitchell[8], Jonathan Hartman[9], David Berry[5], Jochen
Seitz[10], Lukas C. Bossert[9], Thorsten Allers[8], Till Strowig[4,11,12], Birte Abt[3,12], Lorenz C.
Reimer[3], Jörg Overmann[3,12,13], Thomas Clavel[1*]

[1] Functional Microbiome Research Group, Institute of Medical Microbiology, University
Hospital of RWTH Aachen, Germany

[2] Molecular Tumor Biology Research Group, Department of General, Visceral, Children and
Transplantation Surgery, University Hospital of RWTH Aachen, Germany

[3] Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany

[4] Department of Microbial Immune Regulation, Helmholtz Centre for Infection Research,
Braunschweig, Germany

[5] University of Vienna, Center for Microbiology and Environmental Systems Science,
Department of Microbiology and Ecosystem Science, Vienna, Austria

[6] Chair of Nutrition and Immunology, School of Life Sciences, Technische Universität
München, Freising-Weihenstephan, Germany

[7] Institute of Neuroanatomy, University Hospital of RWTH Aachen, Germany

[8] School of Life Sciences, University of Nottingham, Nottingham, UK

[9] IT center, RWTH Aachen, Germany

[10] Clinic for Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy,
LVR-University Hospital Essen, University of Duisburg-Essen, Germany

[11] Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-
Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover,
Germany

[12] German Centre for Infection Research (DZIF), Partner Site Hannover-Braunschweig,
Braunschweig, Germany

[13] Technical University Braunschweig, Braunschweig, Germany

# Authors contributed equally to the manuscript

*Correspondence: tclavel@ukaachen.de

Abstract

Numerous bacteria in the human gut microbiome remains unknown and/or have yet to be cultured. While collections of human gut bacteria have been published, none are publicly accessible. This is partly due to issues with the deposition of strains to public culture collections. We address these key issues (microbial unknowns, lack of public access to isolates) by proposing a framework that facilitates large-scale submission of isolates, exemplified by a rich collection of human gut isolates that is taxonomically described, functionally novel, and made publicly available. An innovative bulk strain submission system was established by large-scale generation and curation of persistent strain identifiers (https://straininfo.dsmz.de). This was used to create the Human intestinal Bacterial Collection (www.hibc.rwth-aachen.de), which contains 340 strains representing 198 species within 29 families and 7 phyla, of which 32 previously unknown taxa are taxonomically described and named. These included three butyrate-producing species of *Faecalibacterium* and new dominant species associated with health and inflammatory bowel disease. Plasmids were identified to be prolific within the HiBC isolates, with almost half (46%) of strains containing one or more plasmids (up to 6). Megaplasmids were identified within two strains, one of them is globally present within multiple *Bacteroidales* species. The strain submission framework and public collection of easily searchable and available gut bacterial isolates presented here will facilitate the work of many by enabling functional studies.

Introduction

The cultivation of human gut bacteria has accelerated in the last years [1–4], providing valuable information on the presence of novel taxa within gut microbiomes. Yet while these published collections of human gut isolates note the novel taxa within their collections [2,5,6], rarely is this novelty made known by naming, describing, and validating the taxa [4]. Curating the taxonomic assignment of such collections is essential as often outdated names are used, or recently described taxa are ignored, causing greater confusion in the current taxonomic sphere [7–9]. Such curated taxonomy ensures strains are correctly assigned, allowing strain-level diversity to be studied [10]. Variation between strains of the same species can lead to functional shifts that alter the association with host dietary habits [11,12]. One way strains can vary is in the presence of mobile genetic elements, which are known to affect the phenotype of the isolates they inhabit [13]. The study of plasmids within the human gut has been limited until recently [14,15].

Accessibility to collections of strains from the human gut is essential for the mechanistic study of microbe-microbe and microbe-host interactions [16–18]. However, accessibility remains problematic, with few strains being deposited in public culture collections and even fewer of the proposed novel taxa being validated. For most of the strains deposited, genomes are available, but their quality is not always high and

metadata such as the source of isolation, cultivation requirements, and full taxonomy
are often lacking. The small number of deposited strains limits future confirmatory or
comparative studies, while the lack of curated metadata reduces the value of the
genomic information. Only the professional acquisition of strains by public collections
can ensure that the high-quality standards required for future work are maintained and
that valuable strain-associated information is gathered and made freely accessible to
researchers and users worldwide. This is particularly relevant for microbiota research
to move beyond associations and towards a more mechanistic understanding, as
exemplified by the study of *Akkermansia muciniphila* [19,20].

The deposit of strains in public collections is a time-demanding and expensive
process, yet necessary to ensure quality. Once deposited, the preservation of strains
becomes a highly cost-effective means of maintaining the value of microbial strains
indefinitely [21]. However, the complete acquisition of single bacterial strains at
international collections, which includes purity and identity confirmation, requires
several months of time and for fastidious anaerobic strains such as those isolated from
the human intestinal microbiome, can be accomplished for only about 20 strains in
parallel by one laboratory technician. This has become a major bottleneck in the
creation of publicly accessible collections emanating from current microbiome
research that generates ever increasing numbers of novel isolates over comparatively
short time intervals. A solution that enables rapid deposition is needed to enhance the
time available to process strains.

To provide functional insights into the human gut microbiome based on isolates and
facilitate public access to strains for the scientific community, we sought to create a
bacterial collection made publicly available more rapidly through an innovative bulk
submission system. In this way, all strains are easily traceable and all their associated
metadata (cultivation conditions, taxonomy, genomic features) are provided. Studying
this collection of isolates provided insight into the prevalence and diversity of plasmids
within the human gut and the presence of megaplasmids. We also highlight health-
associated variation within key genera, including novel species which require further
in vivo study.

Results

A diverse range of key commensal species isolated from the human gut

The Human intestinal Bacterial Collection (HiBC) consists of 340 strains, representing
198 species, isolated from human faecal samples (**Figure 1**). It contains 29 families
from across the seven dominant phyla in the human gut: *Bacillota* (n = 173 isolates),
Bacteroidota (n = 95), *Actinomycetota* (n = 46), *Pseudomonadota* (n = 22),
Desulfobacterota (n = 2), *Fusobacteriota* (n = 1), and *Verrucomicrobiota* (n = 1). Of
the 198 species, 32 are novel taxa that we have described and named for validation
according to both, the SeqCode [7] and the ICNP [22]. High quality genomes, defined as
>90% completeness (99.22 ± 1.10%), <5% contamination (0.50 ± 0.77%), >10x

genome coverage (380.08 ± 293.97), were generated for all 340 strains. To improve access to the strains, their genomes, information on their cultivation, and isolation source material, we have created the HiBC web interface; www.hibc.rwth-aachen.de.

Genome size variation was observed between phyla, with *Actinomycetota* genomes being the smallest (2.38 ± 0.35 Mbp). *Bacteroidota* had the largest genomes (4.97 ± 1.02 Mbp), although not significantly larger than *Pseudomonadota* (4.84 ± 0.64 Mbp; adj. *p* = 0.56) (**Supplementary Figure 1a**; **Supplementary Table 1**). This variation in genome size between phyla was validated using >5,000 previously published genomes [23] (**Supplementary Table 1; Supplementary Figure 1b/c**). In addition to having the largest genomes, *Bacteroidota* also had the largest repertoire of CAZymes (**Supplementary Figure 2b**). To account for the variation in coding potential of each strain, and thereby examine their investment in carbohydrate utilisation, we normalised their CAZyme load based on their number of coding sequences (**Supplementary Figure 2c**). This analysis confirmed that the *Bacteroidota* have the highest investment in carbohydrate utilisation. However, they were followed by the *Actinomycetota* (**Supplementary Table 2**), indicating that, whilst members of this phylum have undergone host-associated genome size reduction [24], they have functionally invested in carbohydrate degradation.

Figure 1: Phylogenomic diversity of isolates within HiBC. Tree based on all 340 genomes, generated using Phylophlan [25]. Phyla are indicated with colours. The *Bacillota* are split due to the placement of *Fusobacteriota,* which separated strains assigned to 'Bacillota_A' by GTDB, suggesting the need for the phylum *Bacillota* to be split. Blue circles identify strains belonging to the 32 novel species that are taxonomically described in this paper. Completeness and contamination of the genomes, as determined using CheckM, are indicated with colour gradients. The size of each genome (Mbp) is plotted as black bars on the outer ring.

Plasmid landscape in the cultured strains and identification of prevalent megaplasmids

Plasmids are known to be present in the human gut and vary between geographically distinct groups [13]. However, most analysis has been culture-independent, preventing accurate taxonomic assignment [14,15,26]. Even studies on horizontal gene transfer using isolates have not reconstructed plasmids and accounted for their impact [27]. As many

bacterial genome assembly workflows do not consider plasmids, we developed a genome pipeline that first searches for the presence of plasmids using Recycler [28] and plasmidSPAdes [29], assembles them, and then removes their reads from consideration during genome assembly (see Methods). This resulted in the reconstruction of plasmids from 46% of the strains (155 out of 340), with a total of 266 plasmids (**Figure 2a**). Plasmids were identified in all phyla except *Fusobacteriota*, for which the HiBC contains only a single isolate. Almost half of the plasmid-containing strains contained more than one plasmid (64 out of 155 strains), up to 6 plasmids in a strain of *Phocaeicola vulgatus* and two strains of the novel species *Enterobacter intestinihominis* (**Figure 2b**).

Given the number of plasmids a single strain can contain, and the size a single plasmid can reach (see below), we hypothesised that they could affect the taxonomic identification of an isolate, as most genomes lack delineation of plasmids. Given the promiscuous nature of plasmids [30], it is possible that the taxonomic signal of a strain may be masked by the presence of multiple large plasmids, distorting taxonomic assignment. As average nucleotide identity (ANI) is a standard approach for taxonomic assignment of genomes, we calculated the theoretical plasmid size required to potentially cause a >1% change in ANI between two genomes of identical size (**Supplementary Figure 3a**). Plasmids >80 kp should theoretically cause such a difference in ANI within genomes ≤8 Mb. To assess this within the HiBC strains, we selected all plasmid-containing strains that had a close relative (determined by GTDB-Tk) (n = 152). We then calculated the ANI to these close relatives, both with and without plasmid inclusion (**Supplementary Figure 3b**). The plasmids had a significant (p = 0.01), but negligible (delta-ANI, 0.004 ± 0.01) effect on reducing the ANI to the closest relative strains. The effect of plasmid inclusion on ANI was independent of cumulative plasmid size, with some small plasmid sets having a greater effect on ANI than the largest (**Figure 2d**). The only strain on which the removal of plasmids had a significant effect was CLA-ER-H4, which was assigned to 'Collinsella sp900547855' by GTDB-Tk when its plasmids were included, but was assigned to 'Collinsella sp003487125' without the plasmids. This is indicative of the need for better taxonomic study of this genus, as the plasmids had no effect on the assignment of CLA-ER-H4 to 'Collinsella sp003487125', but removing the plasmids increased ANI to 'Collinsella sp900547855' by 0.05%. However, to avoid the creation of false species within *Collinsella*, we have not described any new species within this genus, which needs to be done in a comprehensive manner.

Sequence comparison of the HiBC plasmids identified multiple clusters, the two largest of which were specific to the *Bacteroidales* (**Supplementary Figure 4a**). The largest cluster shared similarities with 1,267 plasmids within the comprehensive plasmid database, PLSDB [31], but lacked an assigned name and was therefore named pBAC (plasmid *Bacteroidales*). pBAC was most frequently observed in the USA but was also in Denmark, Japan, Ireland, and China (**Supplementary Figure 4b**). pBAC occurred in both a shorter (~4,220 bp) and longer (~5,419 bp) form, with the two cluster being connected by two 9,494 bp variants. The second largest plasmid cluster was

identified as the cryptic plasmid, pBI143, which is associated with IBD [14] and occurred
in 14 isolates across eight species. Given that pBAC matches 1,266 plasmids within
PLSDB, while pBI143 matched only 719, it may be the most prolific plasmid in the
human gut. Across the 266 plasmids identified in HiBC, 3,697 proteins were predicted,
although only 639 (17.28 %) could be functionally annotated. Of these, nine were
antibiotic resistance genes, four of which were copies of the *APH(2")-IIIa*
aminoglycoside resistance gene found on plasmids of identical size (7,686 bp) in four
strains of *Ruthenibacterium lactatiformans* (strains CLA-KB-H110, CLA-KB-H15, CLA-
KB-H80, CLA-AA-H80).

Megaplasmids (>100 kbp) have been described to occur in lactobacilli [32] and
bifidobacteria [33], but their occurrence in a broader range of commensals from the
human gut is unknown. We evaluated the length of the reconstructed plasmids and
found the average length was 11.74 ± 17.25 kbp (**Figure 2c**). This included the
identification of two megaplasmids, one within a strain of the recently described
species *Hominifimenecus microfluidus* (strain CLA-JM-H9; 125.6 kp) and the other in
a strain of *Phocaeicola vulgatus* (strain CLA-AA-H253; 103.4 kp). The *P. vulgatus*
megaplasmid matched 26 plasmids within PLSDB, including multiple designated as
pMMCAT, a recently proposed large plasmid from *Bacteriodales* which has yet to be
confirmed using sequencing-independent methods [34]. As such, the *P. vulgatus*
megaplasmid was designated pMMCAT_H253. Out of the 104 proteins encoded on
pMMCAT_H253, only 6 could be assigned to a functional category, highlighting the
need for further characterisation of these proteins. A locus containing four proteins
assigned to 'fimbrillin family proteins' was identified within a region of lower GC content
compared to the plasmids average, which may suggest this region is part of the
plasmids additional cargo and not the backbone (**Figure 2e**). While such
megaplasmids have previously been observed in sequencing data of human gut
commensals, their existence is rarely confirmed. To validate the existence of
pMMCAT_H253, we used pulsed field gel electrophoresis (PFGE) which showed a
band of ~100 kb after treatment using XbaI (**Figure 2f**), for which the plasmid had a
single restriction site allowing for its linearisation. The matching pMMCAT plasmids
were observed within species of *Bacteroides*, *Phocaeicola* and *Parabacteroides* from
the USA, China, Japan, and Israel (**Supplementary Figure 4c**). Network analysis of
the pMMCAT plasmids suggested those from *Phocaeicola* were more divergent than
the *Bacteroides* and *Parabacteroides* pMMCAT plasmids (**Supplementary Figure
4d**). MobMess[15] analysis assigned pMMCAT_H253 as a compound plasmid,
supporting the theory that it contains additional cargo, leading to the variable
associations with health conditions for the predicted proteins. A sequence within the
pMMCAT family was detected in 99.55% (1,774/1,782) of human gut metagenomes
[15]. However, only 52 metagenomes had detection values >95%, including two samples
from Fiji, with the highest coverage (135.82x) being from USA samples
(**Supplementary Figure 4e**). These results support the need for greater study of
pMMCAT as a potential source for phenotype variation within genera known to
contribute to host health [35,36].

Figure 2: Plasmid repertoire of human gut bacterial isolates. a. Taxonomic diversity of
reconstructed plasmids at the phylum level. **b.** Number of plasmids reconstructed within each isolate.
c. Length of reconstructed plasmids; a bar represents the number; a line represents the distribution. **d**.
Impact of plasmids on the ANI comparison to each strain's closest match, compared to the cumulative
size of the plasmids within the strain. **e**. Plasmid map of pMMCAT_H253. The innermost rings represent
the association of proteins identified to be differentially prevalent between Crohn's disease (CD)
samples and healthy controls (first ring), or ulcerative colitis (UC) samples and healthy controls (second
ring). Proteins enriched in CD are purple, those enriched in healthy samples are blue, and those
enriched in UC are red. The third ring represents the GC content relative to the average of the entire
plasmid. Boxes are used to represent genes identified on the plasmid in the forward (outer ring) and
reverse (inner ring) strand, with those coloured being assigned a COG category, while grey boxes
represent COG-unassigned proteins. The fimbriae loci proteins are indicated in dark grey. Enzymes
with a single restriction site are indicated on the outer ring in orange. **f.** Pulsed-field gel electrophoresis
of pMMCAT_H253 confirms its presence in the uncut/native form, as well as occurring after gamma
irradiation (to linearise circular DNA), and cut with XbaI (cuts once in pMMCAT_H253). Lambda phage
was used as a marker size ladder.

Description of dominant, as yet unknown taxa within the human gut

The environmental specificity of the isolates was assessed by examining their
presence in 16S rRNA gene amplicon samples for different human body sites (gut,
vagina, lung, skin; n = 1,000 each) (**Supplementary Figure 5**). The high prevalence
of isolates in gut samples confirmed their specificity for this anaerobic environment.
To assess the occurrence of HiBC strains in the human gut in greater detail, we looked

at their prevalence and relative abundance within 1,000 human gut samples (**Figure**
3a). This analysis was complemented by screening the genome of each isolate against
a collection of 42,927 MAGs [23,37]. *Bifidobacterium* spp. were some of the most
prevalent (~70% of samples) and abundant (~9% on average) species. It has
previously been described that cultivation and sequencing approaches capture
different fractions of the human gut; this is highlighted by our ability to isolate a strain
of *Selenomonas noxia*, which was only observed in a single sample, with a relative
abundance <0.1%, making it a sub-dominant member of the gut microbiota, likely of
oral origin [38]. Although only present at an average relative abundance of 2.7%, strains
of *Agathobacter rectalis* (synonym *Eubacterium rectale*) were identified as being the
most frequently reconstructed strain (n = 1,839 MAGs). In contrast, 19 strains did not
match any MAGs, including seven novel taxa. To further assess the importance of
HiBC species to the human gut ecosystem, we screened them against the original
Human Microbiome Projects "most wanted" list of taxa [39]. Of the 1,468 most wanted
sequences, 90 matched HiBC strains, including 4 high, 24 medium, and 62 low priority
sequences. Of these, 8 matching strains represented novel taxa within the phylum
Bacillota according to the current state of nomenclature, including two novel genera
(**Supplementary Figure 6**). These "most wanted" species, and all other novel taxa
discovered in this study are described below (all protologues in the methods).

Next, we assessed the coverage of the entire HiBC collection, as well as just the novel
taxa against a MAG collection for which corresponding relative abundance values
were available for 4,623 individuals. HiBC covered 56.51 ± 20.44 % of an individual's
microbiota. The 32 novel taxa described within this work enhanced this coverage by
4.55 ± 4.17% on average and 150 samples gained >15% relative abundance, which
peaked at more than >40% in two samples (**Figure 3b**). Of the 32 novel taxa, seven
species from five different genera were identified with mean relative abundances
>0.25% within positive metagenomic samples (**Figure 3c**). The most dominant of
these was *Ruminococcoides intestinale* (mean relative abundance = 2.84%; n =
3,023), followed by *Ruminococcoides intestinihominis* (1.19%; n = 285). Although only
recently described [40], these results suggest that *Ruminococcoides* is a dominant but
understudied genus within the human gut. A second genus of clear ecological
importance to the gut is *Lachnospira*, in which we describe two dominant novel
species. Interestingly, the two samples in which novel taxa accounted for >40%
relative abundance were dominated by either *R. intestinale*, or the novel species
Lachnospira rogosae. As *L. rogosae* was also identified as a medium priority, HMP
most wanted taxa and has been associated with human health conditions, such as
myalgic encephalomyelitis [41], further study of this species is needed to quantify its
impact on host health and identify the mechanisms, which is now enabled by this work.

To uncover associations of these taxa with human health conditions, we studied the
ecology of each protein within *R. intestinale* CLA-AA-H216[T] (**Figure 3d**), as the most
abundant novel taxa, and *Blautia intestinihominis* CLA-AA-H95[T] (**Figure 3e**), as
member of a genus associated with both health and disease conditions, using
InvestiGUT[42]. Out of the 2,167 proteins encoded by *R. intestinale* CLA-AA-H216[T],

comparison between Crohn's disease (CD) patients and healthy controls identified a total of 1,902 differentially prevalent proteins, with 1,883 being significantly more prevalent in healthy samples whilst 19 were more prevalent in CD samples. The same pattern was observed with Ulcerative colitis (UC) where a total of 1,715 significantly differentially prevalent proteins were identified, with 1,684 enriched in healthy samples, and 31 enriched in UC samples. Pathway analysis of the health-associated proteins identified multiple anti-inflammatory pathways, including the ABC transporter for spermidine (PotB/C/D), an anti-inflammatory polyamine [43], and biosynthesis of biotin, which has been shown to be immunomodulatory [44,45], ameliorating colitis [46].

The association of *Blautia* spp. with inflammatory bowel diseases is more complex, as some species within this genus have been shown to ameliorate colitis [47], leading to their inclusion within therapeutic products [48]. However, recent studies have suggested some *Blautia* spp. may exacerbate colitis [49]. Given the complex interaction of this genus with inflammatory bowel diseases, we studied the association of the novel species, *B. intestinihominis* CLA-AA-H95^T, with both CD and UC. Out of the 3,906 proteins, comparison between CD patients and healthy controls identified 523 differentially prevalent proteins, with 488 being significantly more prevalent in healthy samples whilst 35 were more prevalent in CD samples. In contrast, comparison between UC patients and healthy controls identified 1466 proteins, with 16 being significantly more prevalent in healthy samples whilst 1,450 were more prevalent in UC samples. The functionality of the large number of proteins enriched within UC samples was studied further, identifying ABC transporters for both branched-chain amino acids (LivF/G/H/K/M) [50], phosphate (PstA/B/C/S) [51], and adenosine (NupA/B/C, BmpA) [52], each of which has been linked to colitis.

These results highlight the relevance of describing novel isolates and provide insights into the observed association of their proteins with health or disease.

Figure 3: Ecology of isolates and novel taxa. a. The prevalence of each HiBC isolate across 16S rRNA amplicon datasets from the human gut (n = 1,000) was plotted against their relative abundance within positive samples. Each point represents a single isolate, coloured by phyla. The size of each point is proportional to the number of human gut MAGs matching the corresponding isolate's genome.

A selection of interesting isolates discussed in this study, or taxonomically coherent isolates, are named. **b.** Cumulative relative abundance of gut metagenomes across 4,624 individuals from Leviatan *et al* (2022) covered by the entire HiBC (left, grey) or the subset represented by novel taxa (right, blue). **c.** Relative abundance of dominant (mean relative abundance >0.25%) novel taxa across 4,624 individuals, with the number of positive samples stated. **d-e.** Genomic location of proteins identified to be significantly differentially prevalent between Crohn's disease (CD) samples and healthy controls (inner ring), or ulcerative colitis (UC) samples and healthy controls (outer ring). The delta-prevalence (prevalence in healthy donors – prevalence in corresponding patients) is shown in blue (more prevalent in healthy controls), red (UC), or mauve (CD). The species, strain, number of proteins predicted within the genome, and those significantly differentially between health conditions are shown within the circle. Only contigs >10kp were plotted.

Enhanced diversity of *Faecalibacterium* species

The genus *Faecalibacterium* currently (March 2024) contains six validly published and correctly named species. HiBC contains representatives for four of these, as well as isolates representing three novel species. Initial 16S rRNA gene analysis assigned these novel species as *Faecalibacterium prausnitzii*, a common commensal of the gut microbiota that has been associated with human health conditions ranging from reducing inflammation [53], to improving cognitive function in Alzheimer's disease [54]. Many of these beneficial observations have been attributed to *F. prausnitzii's* ability to produce large amounts of the short-chain fatty acid butyrate [55].

Taxonomically, the genomic diversity of *F. prausnitzii* is proposed to be greater than suggested by 16S rRNA gene sequence analysis [56]. This has led the GTDB to split this species into 12 proposed species. HiBC contains representatives of the as yet undescribed species defined by GTDB-Tk as *F. prausnitzii* A (strain CLA-AA-H175), *F. prausnitzii* D (strain CLA-JM-H7B), and *F. prausnitzii* J (strain CLA-AA-H281). This was confirmed using ANI and can be observed in a phylogenomic tree (**Figure 4a**). We therefore propose to name these novel species *Faecalibacterium tardum* (CLA-AA-H175), *Faecalibacterium intestinale* (CLA-AA-H281), and *Faecalibacterium faecis* (CLA-JM-H7B). Protologues for these, and the other 29 novel taxa described in this paper are provided at the end of the Methods section. Out of these three *Faecalibacterium* species, *F. faecis* was the most prevalent (93.77% of samples positive) and dominant (relative abundance: 0.77% ± 1.09) **Figure 4b**.

Because of the importance of butyrate production by *Faecalibacterium* spp., we studied this function further (**Figure 4**). While all *Faecalibacterium* strains within HiBC produced butyrate, none of the strains encoded for any butyrate production gut metabolic modules (GMMs; MF0088, MF0089) (**Figure 4c**). To investigate this inconsistency further, we searched a curated list of butyrate production pathways [57] and identified all strains encoded for the acetyl-CoA pathway, but lacked annotations for the terminal enzyme (**Figure 4c**). We extended this to all HiBC strains and identified that 7.4 % of the isolates (n = 25) contained the complete acetyl-CoA pathway (**Supplementary Figure 7**). Taxonomically, we observed that this pathway was restricted to the phylum *Bacillota* (22/25 isolates), except for *Butyricimonas* spp. within the *Bacteroidota*. These results highlight the limitations of current functional

annotation of genomes, even for well-known pathways of interest, such as butyrate production. Next, we measured the ability of all *Faecalibacterium* strains (n = 11) to produce butyrate (**Figure 4c**). Butyrate production varied widely, with *F. tardum* (strain CLA-AAH175) producing only 0.8 ± 0.16 mM, whereas strains of *F. longum* and *F. butyricigenerans* produced >10 mM. The butyrate production patterns were driven by the ability of each strain to grow in the test medium (YCFA). Due to this, we correlated the average butyrate production of each strain against its average growth, measured by OD600 (**Figure 4d**). A strong (*r* = 0.76) and significant (*p* = 0.01) correlation was identified. Interestingly, differences were observed between strains belong to the same species (*F. duncaniae* CLA-AA-H283, 8.67 ± 0.41 mM, OD600 1.31 ± 0.01 *vs.* *F. duncaniae* CLA-AA-H16, 4.25 ± 0.49 mM, OD600 0.52 ± 0.07). These results suggest that interpretations of the ability of different *Faecalibacterium* to produce butyrate *in vitro* should always consider both the exact strain used and its growth ability in the culture medium tested. *In vivo*, this may suggest that strains that grow at high abundance are also likely to produce the most butyrate.

Figure 4: Novel diversity within *Faecalibacterium* and strain-dependent butyrate production. a. The three novel species of *Faecalibacteirum* described within this paper were placed within the current landscape of *Faecalibacterium* with a valid name, along with the type genomes for proposed divisions of *Faecalibacterium prausnitzii*, as determined by GTDB. The phylogenomic tree was rooted on *Ruminococcus bromii* ATCC 27255[T]. Novel species are in bold, and the type strain for *Faecalibacterium prausnitzii* is underlined. **b.** Relative abundance, and prevalence, of the genus *Faecalibacterium*, and each *Faecalibacterium* species represented within HiBC across 4,624 metagenomic samples. **c.** Phylogenomic tree of the *Faecalibacterium* strains within HiBC, displaying the ability of each strain to produce butyrate over a 48h period, along with the OD600 that the strain achieved during the testing period (n = 3 independent batch cultures for each strain; the replicates are shown with individual boxes). The presence of KEGG orthologs (KO) relating to three different pathways for butyrate production is

displayed as a black square, whereas a white square indicates the lack of a KO. The enzymes required
for the acetyl-CoA pathway are: 1. *thl* (K00626, K00632), 2. *bhbd* (K00074), 3. *cro* (K01692, K18122),
4. *bcd* (K00249, K00248), 5. *etfA* (K03522), 6. *etfB* (K03521), 7. *but/buk* (K00929, K18122). The
phylogenomic tree was rooted on *Ruminococcus bromii* ATCC 27255^T. **d.** Correlation of the mean
OD600 against the mean butyrate production of each strain with a linear regression and its 95%
confidence interval.

Bulk submission system enables strain traceability at a large scale

Published isolates, such as those in HiBC, are often not easily accessible to
researchers, impeding them from working with the same quality-controlled strains and
being able to reproduce data. The main barriers to making isolates publicly available
are the time-demanding process of strain deposition and the lack of unique strain
identifiers for transparent referencing of strains while they are being processed.
Researchers frequently deposit only a small selection of strains, preventing access to
functionally relevant diversity, as highlighted above with *Faecalibacterium* (**Figure 4**).
Current strategies for publishing large collections of isolates vary widely, as shown in
Figure 5 (upper box). Publication with a statement such as "available upon request"
without deposition of the strains (case 1) is quick. Still, it should not be accepted
anymore, as the strains and their data are effectively inaccessible and will ultimately
be lost over time. Depositing in an international culture collection (DSMZ, JCM, CCUG,
BCCM, KCCM, ATCC, etc.) ensures metadata quality is maintained and guarantees
the long-term accessibility of the strains for the scientific community. However, if a
publication is released before strains are deposited (case 2) or in parallel (case 3),
there is a risk that deposits will fail (e.g. strains do not grow, are not pure, or their
identity cannot be confirmed), and that different strain identifiers may be used in the
long term, compromising the traceability of the strains. Furthermore, once the work is
published, the lack of incentives often prevents researchers from taking the final and
important step of depositing in a public collection. Current best practice is to ensure
that all strains included in a manuscript are deposited and processed at an
international culture collection before publication, so that strain catalogue numbers
can be issued and included in the manuscript (case 4) [58,59]. The downside of this
approach is that deposition and strain processing for quality checks is time consuming,
and the time required grows linearly with the number of strains to be deposited. The
deposition of a collection such as HiBC is thus a significant undertaking.

We propose a bulk submission system to address these issues and facilitate large-
scale strain deposition, as shown in **Figure 5** (lower box). This new system relies on
stable identifiers provided by the database StrainInfo (https://straininfo.dsmz.de) early
in the process. After an initial check of the strains and curation of the metadata, the
strains data is published as a StrainInfo entry, a persistent StrainInfo (SI) identifiers is
assigned to each strain, and registered as Digital Object Identifiers (DOIs). This initial
step ensures that all data (e.g. publications and sequence data) for these strains can
be linked again later. The bulk submission of strains in one or several collections is
mediated though a new StrainRegistry system, which allows researchers and

collections to interact directly. Like a review system of a scientific journal, this new system accelerates the deposition process by providing all deposition data and communication about it in one place. After a culture collection has accepted a group of strains (or parts of it), it requests the strains from the researcher in batches which are deposited in an iterative process. The StrainInfo database first displays strain entries with the status 'Deposition in progress', which is changed to 'Published' once the strain is available from one or more culture collections. This new system significantly streamlines the deposition process, making it transparent to the outside and provides the persistent identifiers necessary to connect strain data at any time.

Figure 5: Schematic of the proposed submission system for large-scale strain deposition. Once bacteria have been isolated and described, there are multiple strategies for publishing the strains. In the upper box, we have four example strategies, each of which can be applied on a single strain basis, but are not designed for large-scale submission of strains. The benefits and negatives of each method is indicated on the right of the methods under four main categories, where a cross indicates a missing aspect to the strategy. The lower box pictures the main advantage of creating unique strain identifiers early in the process as a foundation for bulk submission of a large number of strains.

Discussion

Over the last decade, the renewed interest in cultivation has expanded the number of genomes available for taxa within the human gut. However, the corresponding strains are rarely accessible to the research community. Deposition of strains within international culture collections has been highlighted as a major limiting factor in making strains publicly available [60]. To overcome this, we established a new deposition system. Streamlined registration of strains before bulk submission ensures their traceability, facilitating publication while ensuring strains are consistently

referenced. Application of this system allowed for deposition of 340 human gut isolates to the German Collection of Microorganisms and Cell Cultures, facilitating the naming and description of 32 novel taxa, consisting of 27 novel species and five novel genera. Based on this, the HiBC is the first publicly accessible collection of human gut isolates.

Large-scale cultivation of human gut bacteria in this study led to isolation of many novel species and genera. Whilst previous cultivation studies report many isolates represent novel diversity, these bacteria are never taxonomically described and named. The discovery of prevalent and important novel species in this work will facilitate future experiments on the role of bacteria in health and disease. This included the isolation of multiple strains of *Faecalibacterium prausnitzii*, a species with the potential to reduce gastrointestinal inflammation[53]. We confirmed that this species is actually a diverse group of related species that show reduced 16S rRNA gene sequence diversity [56]. By naming three of these species and describing the butyrate production and growth characteristics of seven different species in this genus, we observed the ability of these strains to produce butyrate was proportional to their ability to grow. Given these results, further quantification of these strains ability to grow within the human gut is required to understand their contribution to SCFA levels *in vivo*, and therefore their potential impact on host health.

The reconstruction of plasmids for each of these strains allows for the direct link of plasmids to strains of various species, key information previously lacking from studies into plasmids within human gut [13–15]. Plasmids were identified to be highly prevalent within human gut isolates, occurring within almost all phyla represented within the HiBC, with as many as six occurring within a single strain. By making the reconstructed plasmids, and strains publicly available, we believe this resource expands the toolbox of methods for genetically modifying non-model commensal gut microbes.

Metagenomic studies of the human gut have provided various insights into the taxonomic and functional diversity present, however, they are unable to provide mechanistic insights. By providing researchers access to a collection of human gut isolates, the functionality of taxa can be experimentally validated, facilitating mechanistic study of host-microbe interactions.

Methods

Ethics

The Ethics Committee of the Medical Faculty of RWTH University Aachen permitted bacterial isolation from human stool under ethical number EK 23-055, EK 316-16, and EK 194/19. For strains originating from Vienna, isolation was approved by the University of Vienna ethics committee under ethical number 00161. For strains originating from Braunschweig, isolation was approved by the Ethics Committee of Lower Saxony (MHH permit No. 6794, 8629, and 8750). Written informed consent was signed by all enrolled participants.

Bacterial isolation and cultivation

Human stool was collected in sterile plastic bags and stored in tightly sealed plastic buckets until further processing. An oxygen scavenger sachet (BD Biosciences; ref. 260683) was added to each bucket before sealing to reduce exposure to oxygen. All samples were processed in the lab within 24 hours of collection. First the faecal material was homogenized by manual kneading of the plastic bag. Stool samples were either mixed 1:5 with anaerobic FMT media[61], distributed to 1 mL aliquots and stored at -80 °C until further use, or the samples were further processed as described previously[59]. Hence approximately 5 g of the samples were dissolved in 50 ml of anaerobic PBS supplemented with peptone (0.05% w/v), L-cysteine (0.05% w/v) and dithiothreitol (DTT) (0.02% w/v) by shaking the glass flask intensely. A syringe with needle was used to transfer 5 ml of the slurry through a rubber stopper (previously flamed using ethanol) into a second glass flask containing 45 ml of the same buffer in an anaerobic atmosphere (89.3% N_2, 6% CO_2, 4.7% H_2) to create a 1:100 dilution of the original sample. The flask was moved into an anaerobic workstation (MBraun GmbH, Germany) to prepare 2 ml aliquots under anaerobic conditions, which were mixed with 2 ml of 40% anaerobic glycerol to a final concentration of 20%, then stored at -80 °C until use.

Two different approaches were used for bacterial isolation. For classical isolation, the faecal aliquots were thawed inside the anaerobic workstation and diluted with anoxic PBS (see above) in a tenfold dilution series (10^{-2} to 10^{-6}). 50 µl of each dilution step were transferred onto different agar plates and spread using a L-spatula. Single colonies were picked after 1-7 days of incubation at 37 °C under anaerobic conditions. Bacterial cells were re-streaked at least three times to guarantee purity of the culture. For the second isolation approach, the single-cell dispenser b.sight (Cytena GmbH, Germany) was used as described before [62]. Details on culture media preparation and ingredients are provided in the **Supplementary Methods**.

The isolated bacteria were first identified using MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). If a species was not yet present within HiBC, or could not be reliably identified by MALDI-TOF MS, the bacteria were stored as cryo-stocks and DNA extracted for genome sequencing. Cryo-stocks were generated by freezing in glycerol media (end concentration 20%) at -80 °C. All HiBC strains have been deposited at the Leibniz Institute DSMZ, German Collection of Microorganisms and Cell Cultures. In addition, the strains representing novel taxa were deposited at either the Belgian Coordinated Collections of Microorganisms (BCCM) or the Japanese Collection of Microorganisms (JCM).

Metabolite production analysis

Concentrations of short-chain fatty acids (SCFAs) (acetate, butyrate, propionate, valerate), branched chain fatty acids (isobutyrate, isovalerate), intermediate metabolites (ethanol, formate, lactate, 1,2-propandiol, 1-propanol, succinate), as well

as mono- and disaccharides (galactose, glucose, lactose) were measured by high-performance liquid chromatography (HPLC). The bacterial strains were grown anaerobically, apart from *Robertmurraya yapensis* CLA-AA-H227 which was grown under aerobic conditions, in YCFA broth (DSMZ Medium No. 1611) in Hungate tubes for 48 hours at 37 °C. Triplicate cultures from each strain were measured. Baseline controls were taken from each sterile Hungate tube before inoculation. Each taken sample was centrifuged (10,000 x g, 10 min, 4 °C), supernatants were collected and stored at -80 °C until HPLC measurement. Samples were prepared and measured (including HPLC settings) as described previously [59]. External standards were used for concentration determination by comparison of peak retention times (HPLC grade compounds were purchased from Sigma-Aldrich). Peaks were integrated using the Chromaster System Manager Software (Version 2.0, Hitachi High-Tech Science Corporation 2013, 2017). Metabolite concentrations >0.2 mM (limit of detection (LOD) for citrate, 1-propanol), >0.24 mM (LOD for butyrate, formate, galactose, glucose, isobutyrate, isovalerate, lactose, valerate), >0.4 mM (ethanol, 1,2-propandiol) and >0.8 mM (acetate, lactate, propionate, succinate) were considered for statistical analysis if present in all three replicates. Production and consumption of metabolites was calculated by subtracting the baseline values from the sample taken after 48 hours of growth.

Isolation of genomic DNA

DNA was isolated using a modified protocol according to Godon *et al*. [63]. Frozen cell pellets were mixed with 600 µl stool DNA stabilizer (Stratec biomedical), thawed, and transferred into autoclaved 2-ml screw-cap tubes containing 500 mg 0.1 mm-diameter silica/zirconia beads. Next, 250 µL 4 M guanidine thiocyanate in 0.1 M Tris (pH 7.5) and 500 µL 5 % N-lauroyl sarcosine in 0.1 M PBS (pH 8.0) were added. Samples were incubated at 70 °C and 700 rpm for 60 min. A FastPrep® instrument (MP Biomedicals) fitted with a 24 × 2 ml cooling adaptor filled with dry ice was used for cell disruption. The program was run 3 times for 40 s at 6.5 M/s. After each run, the cooling adapter was refilled with dry ice. An amount of 15 mg Polyvinylpyrrolidone (PVPP) was added and samples were vortexed, followed by 3 min centrifugation at 15.000 x g and 4 °C. Approximately 650 µl of the supernatant were transferred into a new 2 ml tube, which was centrifuged again for 3 min at 15.000 x g and 4 °C. Subsequently, 500 µl of the supernatant was transferred into a new 2 ml tube and 50 µg of RNase was added. After 20 minutes at 37 °C and 700 rpm, gDNA was isolated using the NucleoSpin® gDNA Clean-up Kit from Macherey-Nagel. Isolation was performed according to the manufacturer's protocol. DNA was eluted from columns twice using 40 µl Elution buffer and concentration was measured with NanoDrop® (Thermo Scientific). Samples were stored at -20 °C.

Genome library preparation and Illumina Sequencing

Library preparation and sequencing were conducted using the NEBNext Ultra II FS
DNA Library Prep Kit for Illumina with dual index primers and ~300 ng of DNA (NEB
Inc.) on an automation platform (Biomeki5, Beckman Coulter) according to the
manufacturer's instructions. The time used for enzymatic shearing to ca. 500 bp to be
used on a MiSeq run was 10 minutes and to ca. 200 bp to be used on a NextSeq run
was 30 minutes. PCR enrichment of adaptor-ligated DNA was conducted with five
cycles using NEBNext Multiplex Oligos for Illumina (NEB, USA) for paired-end
barcoding. AMPure beads (Beckman Coulter, USA) were used for size selection and
clean-up of adaptor-ligated DNA. Sequencing was performed either at the IZKF Core
Facility Genomics (Uniklinik RWTH Aachen) on an NextSeq platform (Illumina) (PE
150 bp), or on a MiSeq (Illumina) (PE 300 bp) in house.

Sequencing data processing

Genomes were assembled from paired-end Illumina short-reads. Low-quality reads
with an expected average quality below 20 over a 5-bases window, containing
adapters, and shorter than 50 bases were discarded using Trimmomatic (v0.39) [64].
Reads with phiX sequences were removed using BBduk from the BBtools suite [65].
Plasmids sequences were reported only when inferred from plasmidSPades (v3.15.5)
[66] and then from Recycler (v0.7) [28]. Reads free from plasmid sequences were then
assembled using SPades (v3.15.5) [29] with default parameters.

Contigs above 500 bp in assemblies were kept for quality evaluation. Following the
MIxS specifications [67] as well as requirements from the SeqCode [7], genomes with a
coverage above 10X, a completion above 90%, and a contamination below 5% based
on CheckM (v1.2.2) [68] estimation using single-copy marker genes were flagged as
high-quality draft genomes. Additional quality flags on the assembly included: 1) <100
contigs, longest contig >100 kbp, and N50 >25 kbp using QUAST (v5.0.2) [69]; 2)
detectable 16S and 23S rRNA genes using metaxa2 (v2.2.3) [70]; 3) >18 unique
essential tRNAs genes and a detectable 5S rRNA gene sequence using the
annotations of bakta (v1.6.1) [71].

The genome assembly pipeline, including the reconstruction of plasmids and quality
checks steps, is available as a reproducible workflow using Snakemake (v7.9.0) [72]:
https://github.com/clavellab/genome-assembly.

Genome analysis

Taxonomic, functional, and ecological analysis for all genomes was conducted using
Protologger (v1.3) [73]. For this, 16S rRNA gene sequences were extracted from each
strains genome using barrnap v0.9 (default settings)
(https://github.com/tseemann/barrnap), and the longest 16S rRNA gene sequence
from each genome was used as input for Protologger. Phylogenomic trees were
generated using Phylophlan v3.0.60 [74] with proteomes predicted using Prodigal v2.6.3

(default settings) [75]. Gut metabolic modules presence was based on the identification
of all included KOs within a genome, detected by Kofamscan v1.3.0 [76].

<u>Plasmid analysis</u>

Sequence similarity between the isolates plasmids was determined using MobMess [15]
and clusters were visualised with Cytoscape [77]. Clustering was conducted firstly based
only on the isolate plasmids, and then including the background previously predicted
human gut plasmids.

The similarity of each plasmid to known sequences was determined with the 'mash
dist' option of PLSDB (v2023_11_03_v2) [31]. The ecology of each plasmid was inferred
from the geographical location assigned to each matching plasmid.

<u>Pulsed Field Gel Electrophoresis</u>

Cultures were grown overnight in 5 mL BHI media, centrifuged (2 mL for *P. vulgatus*
CLA-AA-H253, 5 mL for *H. microfluidus* CLA-JM-H9), resuspended in 100 µL sterile
PBS and incubated at 45 °C for 10 minutes. Of this, 80 µL was mixed with 320 µL 1%
agarose (Bio-Rad Certified Megabase Agarose) at 45 C, 80 µL transferred to PFGE
plug moulds (Bio-Rad CHEF Disposable Plug Molds, 50-Well) and cooled at 4 °C for
30 minutes. Solidified agarose plugs were transferred to lysis solution inside 2 mL
microcentrifuge tubes (20 mM Tris-HCl pH 8.8, 500 mM EDTA pH 8, 1% N-
laurylsarcosine, 1mg/mL Proteinase K) and incubated with shaking at 250 RPM at 45
°C for 4 hours. Lysis solution was replaced with fresh lysis solution + RNAse (10
µg/mL) and incubated with shaking at 45 °C overnight. Lysis solution was replaced
with wash solution (25 mM Tris-HCl pH 7.5, 100 mM EDTA pH 8) and incubated with
shaking at 45 °C. Plugs were then transferred to fresh 2 mL microcentrifuge tubes with
wash solution containing phenylmethanesulfonyl fluoride (1 mM) and incubated with
shaking at 45 °C for 30 minutes, twice. Plugs were then transferred to 1 mL wash
solution at stored at 4 °C until use in PFGE.

For analysis of intact genomic DNA, agarose plugs were subjected to 100 Gy of γ
radiation using a ^{137}Cs source (Gammacell 1000), to linearize circular chromosomes
[78]. PFGE was performed using a CHEF Mapper apparatus (Bio-Rad). Intact and XbaI-
digested DNA fragments were separated on a 1.2% agarose gel in 0.5 × TBE at 14 °C,
with a gradient voltage of 6 V/cm, linear ramping, an included angle of 120°, initial and
final switch times of 0.64 s and 1 min 13.22 s, respectively, and a run time of 20 h 46
min.

<u>Website design</u>

Access to taxonomic, cultivation, and genomic information about the HiBC strains is
available at: https://www.hibc.rwth-aachen.de. This website was created using the

Shiny package from R. The 16S rRNA gene sequence and genome for each strain
can be downloaded directly from this site, both individually for strains of interest via
the research data management platform Coscine, or for the entire collection via the
digital repository Zenodo. Further strain specific metadata provided includes: isolation
conditions, source, and risk group.

<u>Description of novel taxa</u>

The description of novel taxa was based on the analysis provided by Protologger v1.3
[73], and manually curated into the protologues below. For each isolate, taxonomy was
assigned using the following thresholds: <98.7% 16S rRNA gene sequence identity
(as indication for as yet undescribed species), <94.5% (undescribed genus), and
<86.5% (undescribed family) [79]. ANI values <95% to separate species [80]; POCP
values <50% for distinct genera [81]. Phylogenomic trees were also considered to make
decisions on genus- and family-level delineation [25]. All novel taxa have been
registered with the SeqCode and will be registered with the ICNP.

Description of *Alistipes intestinihominis* sp. nov.

Alistipes intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, the intestine; L.
masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human intestine).

The genome size is 3.85 Mbp, G+C percentage is 58.29%, with 99.76% completeness
and 0.96% contamination. Strain CLA-KB-H122 was determined to be a new species
based on 16S rRNA gene analysis, with the closest validly named match being
Alistipes timonensis (98.17%). Separation from existing *Alistipes* species was
confirmed by ANI comparison, which gave a value of 91.78% to *A. timonensis*. GTDB-
Tk classified strain CLA-KB-H122 as 'Alistipes senegalensis'. However, the latter
name is as yet not valid. Functional analysis showed the strain has 83 transporters,
17 secretion genes, and predicted utilization of cellulose and starch along with
production of L-glutamate and folate. In total, 395 CAZymes were identified, with 59
different glycoside hydrolase families and 19 glycoside transferase families
represented. The type strain, CLA-KB-H122^T (phylum *Bacteroidota*, family
Rikenellaceae) (StrainInfo: 10.60712/SI-ID414389.1, genome: GCA_040095975.1),
was isolated from human faeces.

Description of *Bifidobacterium hominis* sp. nov.

Bifidobacterium hominis (ho'mi.nis. L. gen. n. *hominis*, of a human being, pertaining to
the human gut habitat, from where the type strain was isolated).

The genome size is 2.03 Mbp, G+C percentage is 55.98%, with 99.77% completeness
and 0.45% contamination. The closest relative to strain CLA-AA-H311 was
Bifidobacterium pseudocatenulatum (99.07%) based on 16S rRNA gene analysis.

However, ANI comparison identified strain CLA-AA-H311 as a novel species within the genus *Bifidobacterium*, with an ANI value of 93.18% against *B. pseudocatenulatum*. GTDB-Tk classification as 'Bifidobacterium sp002742445' confirmed the proposition of a novel species. Placement within the genus *Bifidobacterium* was confirmed by the presence of fructose-6-phosphate phosphoketolase (KO1621) [82]. Functional analysis showed the strain has 90 transporters, 20 secretion genes, and predicted utilization of starch and production of propionate, acetate, and folate. In total, 137 CAZymes were identified, with 28 different glycoside hydrolase families and 11 glycoside transferase families represented. The type strain, CLA-AA-H311[T] (phylum *Actinomycetota*, family *Bifidobacteriaceae*) (=DSM 118068) (StrainInfo: 10.60712/SI-ID414317.1, genome: GCA_040095915.1), was isolated from human faeces.

Description of *Blautia aquisgranensis* sp. nov.

Blautia aquisgranensis (a.quis.gra.nen'sis. L. masc. adj. *aquisgranensis,* named after the German city of Aachen where it was isolated)

The genome size is 3.63 Mbp, G+C percentage is 43.76%, with 99.37% completeness and 0.32% contamination. It includes two plasmids (37,495 bp; 1,036 bp). The closest relative to strain CLA-JM-H16 was *Blautia intestinalis* (96.11%) based on 16S rRNA gene analysis. Placement of the strain within *Blautia* was confirmed based on POCP comparison as values above 50% to multiple *Blautia* species were obtained. However, comparison to the type species of the genus, *Blautia coccoides*, gave a value of 42.36%. This inconsistency was also highlighted by GTDB-Tk, which classified strain CLA-JM-H16 as 'Blautia_A sp900764225', suggesting *Blautia* may require splitting into multiple genera in future. As the separation of *Blautia* would require detailed analysis which is outside the scope of this manuscript, we propose strain CLA-JM-H16 as a novel species within *Blautia*. All three novel species of *Blautia* described within this manuscript were confirmed to represent distinct species based on ANI comparison (*B. aquisgranensis* Vs. *B. caccae*, 81.74%; *B. aquisgranensis* Vs. *B. intestinihominis*, 76.95%; *B. caccae* Vs. *B. intestinihominis*, 78.57%). Functional analysis revealed 157 transporters, 17 secretion genes, and predicted utilization of arbutin, salicin, sucrose, starch, and production of acetate, propionate, folate, L-glutamate, riboflavin, and cobalamin. In total, 205 CAZymes were identified, with 40 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-JM-H16[T] (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 114586, =LMG 33033) (StrainInfo: 10.60712/SI-ID414368.1, genome: GCA_040096615.1), was isolated from human faeces.

Description of *Blautia caccae* sp. nov.

Blautia caccae (cac'cae. N.L. fem. n. *cacca*, human ordure, feces; from Gr. fem. n.
kakkê, human ordure, feces; N.L. gen. n. *caccae*, of feces, referring to the source of
isolate).

The genome size is 5.83 Mbp, G+C percentage is 46.73%, with 98.73% completeness
and 0.63% contamination. The closest relative to strain CLA-SR-H028 was *Blautia*
hominis (98.66%) based on 16S rRNA gene analysis. ANI comparison identified CLA-
SR-H028 as a novel species within the genus *Blautia*, with all values being below the
species threshold. GTDB-Tk classification as 'Blautia sp001304935' confirmed the
proposition of a novel species within *Blautia*. Functional analysis showed the strain
has 158 transporters, 18 secretion genes, and predicted utilization of cellobiose,
sucrose, starch and production of propionate, acetate, cobalamin, and folate. In total,
353 CAZymes were identified, with 53 different glycoside hydrolase families and 15
glycoside transferase families represented. The type strain, CLA-SR-H028^T (phylum
Bacillota, family *Lachnospiraceae*) (Straininfo: 10.60712/SI-ID414428.1, genome:
GCA_040095955.1), was isolated from human faeces.

Description of *Blautia intestinihominis* sp. nov.

Blautia intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, intestine; L. masc.
n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human intestine).

The genome size is 4.1 Mbp, G+C percentage is 43.49%, with 98.73% completeness
and 0.63% contamination. It includes a single plasmid of 22,629 bp. The isolate was
assigned to the species *Blautia obeum* (98.98%) based on 16S rRNA gene analysis.
However, ANI comparison to *B. obeum* clearly identified this isolate as being a
separate species (84.16%). This was confirmed by GTDB-Tk classification as
'Blautia_A sp000436615', recommending the creation of a novel species. Functional
analysis showed the strain has 155 transporters, 18 secretion genes, and predicted
utilization of sucrose and starch, along with production of L-glutamate, folate,
propionate, and cobalamin. In total, 177 CAZymes were identified. The type strain,
CLA-AA-H95^T (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 111354) (StrainInfo:
10.60712/SI-ID414326.1, genome: GCA_040096655.1), was isolated from human
faeces.

Description of *Coprococcus intestinihominis* sp. nov.

Coprococcus intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, intestine; L.
masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human intestine).

The genome size is 3.6 Mbp, G+C percentage is 43.29%, with 98.43% completeness
and 2.52% contamination. A single plasmid of 20,255 bp was detected. The closest
relative to strain CLA-AA-H190 was *Coprococcus catus* (96.76%) based on 16S rRNA
gene analysis. ANI comparison identified CLA-AA-H190 as a novel species within the
genus *Coprococcus*, with an ANI value of 90.25% against the closest relative *C. catus*.

GTDB-Tk classification as 'Coprococcus_A catus_A' confirmed the proposition of a
novel species, but also suggests that separation of *Coprococcus* into multiple genera
could occur in future. Functional analysis showed the strain has 119 transporters, 18
secretion genes, and predicted utilization of starch and production of propionate,
butyrate, acetate, cobalamin, and folate. In total, 122 CAZymes were identified, with
19 different glycoside hydrolase families and 13 glycoside transferase families
represented. The type strain, CLA-AA-H190^T (phylum *Bacillota*, family
Lachnospiraceae) (=DSM 114688, =LMG 33015) (StrainInfo: 10.60712/SI-
ID414125.1, genome: GCA_040096555.1), was isolated from human faeces.

Description of *Enterobacter intestinihominis* sp. nov.

Enterobacter intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, the
intestine; L. masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the
human intestine).

The genome size is 4.86 Mbp, G+C percentage is 54.88%, with 99.89% completeness
and 0.12% contamination. It contains two plasmids (4,416 bp; 2,494 bp). Strain CLA-
AC-H004 was determined to be a strain of *Enterobacter quasihormaechei* (99.80%)
based on 16S rRNA gene analysis. Separation from existing *Enterobacter* species
was confirmed by ANI comparison, which gave a value of 93.69% to *E.*
quasihormaechei. GTDB-Tk classification of strain CLA-AC-H004 as 'Enterobacter
hormaechei_A' supports the proposal of a novel species. Functional analysis showed
the strain has 497 transporters, 98 secretion genes, and predicted utilization of arbutin,
salicin, cellobiose, sucrose, and starch along with production of L-glutamate, biotin,
riboflavin, acetate, propionate, and folate. In total, 316 CAZymes were identified, with
37 different glycoside hydrolase families and 19 glycoside transferase families
represented. The type strain, CLA-AC-H004^T (phylum *Pseudomonadota*, family
Enterobacteriaceae) (StrainInfo: 10.60712/SI-ID414328.1, genome:
GCA_040096145.1), was isolated from human faeces.

Description of *Enterocloster hominis* sp. nov.

Enterocloster hominis (ho'mi.nis. L. gen. n. *hominis*, of a human being).

The genome size is 6.52 Mbp, G+C percentage is 50.14%, with 99.16% completeness
and 2.53% contamination. It includes a single plasmid of 7,635 bp. The closest relative
to strain CLA-SR-H021 was *Enterocloster aldenensis* (98.44%) based on 16S rRNA
gene analysis. ANI comparison identified CLA-SR-H021 as a novel species within the
genus *Enterocloster*, with all values being below the species threshold. GTDB-Tk
classified CLA-SR-H021 as 'Enterocloster pacaense', a name derived from the
proposed species 'Lachnoclostridium pacaense'. However, the fact that these two
names are not valid supports the proposition of a novel species within *Enterocloster*.
Functional analysis revealed 118 transporters, 14 secretion genes, and predicted
utilization of cellobiose, starch and production of propionate, acetate, and folate. In

total, 307 CAZymes were identified, with 39 different glycoside hydrolase families and 14 glycoside transferase families represented. The type strain, CLA-SR-H021^T (phylum *Bacillota*, family *Lachnospiraceae*) (StrainInfo: 10.60712/SI-ID414422.1, genome: GCA_040096035.1), was isolated from human faeces.

Description of *Faecalibacterium faecis* sp. nov.

Faecalibacterium faecis (fae'cis. L. gen. fem. n. *faecis*, of dregs, pertaining to faeces, from where the type strain was isolated).

The genome size is 2.71 Mbp, G+C percentage is 56.23%, with 100.0% completeness and 0.0% contamination. The isolate was determined to be similar to *Faecalibacterium butyricigenerans* (99.57%) based on 16S rRNA gene analysis. However, ANI similarity to *F. butyricigenerans* was 84.61% and the closest relative based on ANI comparison was *F. prausnitzii* (87.03%). These values are below the threshold for species assignment, suggesting the creation of a novel species. This was supported via GTDB-Tk classification of the isolate as 'Faecalibacterium prausnitzii_D'. Functional analysis showed the strain has 130 transporters, 16 secretion genes, and predicted utilization of cellobiose, starch, and production of L-glutamate, riboflavin, and cobalamin. Production of butyrate (6.12 ± 0.53 mM) was confirmed for strain CLA-JM-H7B when grown in YCFA broth (DSMZ Medium No. 1611) in Hungate tubes for 48 hours at 37 °C under anaerobic conditions (6% CO_2 and 4,7% H_2 in N_2). In total, 157 CAZymes were identified, with 25 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-JM-H7-B^T (phylum *Bacillota*, family *Oscillospiraceae*) (=DSM 114587) (StrainInfo: 10.60712/SI-ID414382.1, genome: GCA_040096475.1), was isolated from human faeces.

Description of *Faecalibacterium intestinale* sp. nov.

Faecalibacterium intestinale (in.tes.ti.na'le. N.L. neut. adj. *intestinale*, pertaining to the intestine, from where the type strain was isolated).

The genome size is 2.97 Mbp, G+C percentage is 56.43%, with 100.0% completeness and 0.0% contamination. The isolate was determined to be related to *F. prausnitzii* (98.08%) based on 16S rRNA gene analysis. ANI comparison to *F. prausnitzii* was just below species level assignment (94.46%), and GTDB-Tk classification as 'Faecalibacterium prausnitzii_J' recommended the creation of a novel species. Functional analysis showed the strain has 135 transporters, 18 secretion genes, and predicted utilization of starch and production of L-glutamate, riboflavin, and cobalamin. Production of butyrate (4.74 ± 0.30 mM) was confirmed for strain CLA-AA-H281 when grown in YCFA broth (DSMZ Medium No. 1611) in Hungate tubes for 48 hours at 37 °C under anaerobic conditions (6% CO_2 and 4,7% H_2 in N_2). In total, 159 CAZymes were identified, with 27 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-AA-H281^T (phylum *Bacillota*,

family *Oscillospiraceae*) (=DSM 116193, =LMG 33027) (StrainInfo: 10.60712/SI-ID414306.1, genome: GCA_040096575.1), was isolated from human faeces.

Description of *Faecalibacterium tardum* sp. nov.

Faecalibacterium tardum (tar'dum. L. neut. adj. tardum, pertaining to its slow growth).

The genome size is 3.04 Mbp, G+C percentage is 56.28%, with 99.32% completeness and 0.0% contamination. It contains one plasmid of 14,735 bp in size, which encodes for vancomycin resistance via the *vanY* gene. The isolate was determined to be closely related to *Faecalibacterium prausnitzii* (98.70%) based on 16S rRNA gene analysis. ANI comparison to *F. prausnitzii* was on the border of species level assignment (95.05%), however, GTDB-Tk classification as 'Faecalibacterium prausnitzii_A' recommended the creation of a novel species. Strain CLA-AA-H175 was confirmed to represent a distinct species to *Faecalibacterium intestinale* (CLA-AA-H281) (ANI: 94.39%) and *Faecalibacterium faecis* (CLA-JM-H7B) (ANI: 86.46%), also described in this paper. Functional analysis showed the strain has 116 transporters, 18 secretion genes, and predicted utilization of starch, and production of L-glutamate. Production of butyrate (0.81 ± 0.16 mM) was confirmed for strain CLA-AA-H175 when grown in YCFA broth (DSMZ Medium No. 1611) in Hungate tubes for 48 hours at 37 °C under anaerobic conditions (6% CO_2 and 4,7% H_2 in N_2). In total, 177 CAZymes were identified, with 28 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-AA-H175^T (phylum *Bacillota*, family *Oscillospiraceae*) (=DSM 116192) (StrainInfo: 10.60712/SI-ID414281.1, genome: GCA_040096515.1), was isolated from human faeces.

Description of *Faecousia* gen. nov.

Faecousia (Faec.ou'si.a. L. fem. n. *faex*, dregs; Gr. fem. n. *ousia*, an essence; N.L. fem. n. *Faecousia*, a microbe associated with faeces).

Based on 16S rRNA gene sequence identity, the closest relatives are members of the genus *Vescimonas* (*Vescimonas fastidiosa*, 93.48%). POCP analysis against *Vescimonas coprocola* (44.75%), the type species of this genus, and *V. fastidiosa* (41.06%) confirmed strain CLA-AA-H192 represents a distinct genus to *Vescimonas*. GTDB-Tk supported the creation of a novel genus, placing strain CLA-AA-H192 within the proposed genus of "*Candidatus Faecousia*". The type species of this genus is *Faecousia intestinalis*.

Description of *Faecousia intestinalis* sp. nov.

Faecousia intestinalis (in.tes.ti.na'lis. N.L. fem. adj. *intestinalis*, pertaining to the intestines, from where the type strain was isolated).

The genome size is 2.98 Mbp, G+C percentage is 58.44%, with 93.29% completeness and 0.0% contamination. It contains two plasmids (23,094 bp; 3,448 bp). Functional analysis showed the strain has 144 transporters, 26 secretion genes, and predicted utilization of starch, and production of acetate, propionate, L-glutamate, and folate. In total, 116 CAZymes were identified, with 19 different glycoside hydrolase families and 11 glycoside transferase families represented. The type strain, CLA-AA-H192^T (phylum *Bacillota*, family *Oscillospiraceae*) (StrainInfo: 10.60712/SI-ID414286.1, genome: GCA_040096185.1), was isolated from human faeces.

Description of *Flavonifractor hominis* sp. nov.

Flavonifractor hominis (ho'mi.nis. L. gen. n. *hominis*, of a human being).

The genome size is 2.94 Mbp, G+C percentage is 58.64%, with 99.33% completeness and 0.0% contamination. Strain CLA-AP-H34 was determined to be a new species based on 16S rRNA gene sequence analysis, with the closest validly named match being *Flavonifractor plautii* (97.21%). Separation from existing *Flavonifractor* species was confirmed by ANI comparison, which gave a value of 82.25% to *F. plautii*. GTDB-Tk classification of strain CLA-AP-H34 as an unknown species within *Flavonifractor* supports the proposal of a novel species. Functional analysis showed the strain has 112 transporters, 14 secretion genes, and predicted utilization of starch and production of L-glutamate, riboflavin, butyrate, and folate. In total, 140 CAZymes were identified, with 19 different glycoside hydrolase families and 15 glycoside transferase families represented. The type strain, CLA-AP-H34^T (phylum *Bacillota*, family *Oscillospiraceae*) (StrainInfo: 10.60712/SI-ID414347.1, genome: GCA_040095835.1), was isolated from human faeces.

Description of *Hominicola* gen. nov.

Hominicola (Ho.mi.ni.co.la. L. masc. n. homo, human being, man L. fem. n. suff. -cola, inhabitant, deweller; N.L. fem. n. *Hominicola*, a microbe dwelling within human beings).

Based on 16S rRNA gene sequence identity, the closest relative is *Negativibacillus massiliensis* (94.53%), the type and singular species within the genus *Negativibacillus* within the *Bacillota*. POCP analysis confirmed strain CLA-JM-H45 represents a distinct genus to *Negativibacillus,* with 43.21% to *N. massiliensis*. GTDB-Tk supported the creation of a novel genus, placing strain CLA-AA- H45 within the genus '*Phocae'*, which is an invalid name. Therefore, creation of the genus *Hominicola* within family *Oscillospiraceae* is proposed to accommodate this isolate. The type species of this genus is *Hominicola intestinalis*.

Description of *Hominicola intestinalis* sp. nov.

Hominicola intestinalis (in.tes.ti.na'lis. N.L. fem. adj. *intestinalis*, pertaining to the
intestines, from where the type strain was isolated).

The genome size is 2.24 Mbp, G+C percentage is 56.25%, with 95.3% completeness
and 0.67% contamination. It contains a plasmid (3,541 bp). Functional analysis
showed the strain has 95 transporters, 13 secretion genes, and predicted utilization of
starch, and production of acetate, propionate, L-glutamate, and cobalamin. In total, 79
CAZymes were identified, with 15 different glycoside hydrolase families and 11
glycoside transferase families represented. The type strain, CLA-JM-H45^T (phylum
Bacillota, family *Oscillospiraceae*) (=DSM 114602, =LMG 33035) (StrainInfo:
10.60712/SI-ID414378.1, genome: GCA_040096325.1), was isolated from human
faeces.

Description of *Hominiventricola aquisgranensis* sp. nov.

Hominiventricola aquisgranensis (a.quis.gra.nen'sis. L. masc. adj. *aquisgranensis,*
named after the German city of Aachen where it was isolated).

The genome size is 3.17 Mbp, G+C percentage is 45.01%, with 99.37% completeness
and 0.27% contamination, including a single plasmid of 7,983 bp. The closest relative
to strain CLA-AA-H78B was *Hominiventricola filiformis* (96.24%) based on 16S rRNA
gene analysis. POCP analysis confirmed genus assignment to *Hominiventricola*, with
a POCP value of 69.06% to the type strain of the only current species within this genus,
H. filiformis. GTDB-Tk classified strain CLA-AA-H78B as 'Choladocola sp003480725'
within "*Candidatus* Choladocola". The latter is a heterosynonym of *Hominiventricola*,
a validly published name. ANI comparison confirmed that strain CLA-AA-H78B
represents a novel species as the ANI value to *H. filiformis* was 82.98%. Functional
analysis showed the strain has 134 transporters, 31 secretion genes, and predicted
utilization of cellobiose, starch, arbutin, salicin, and production of L-glutamate, folate,
acetate, propionate, and cobalamin. In total, 134 CAZymes were identified. The type
strain, CLA-AA-H78B^T (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 111355)
(StrainInfo: 10.60712/SI-ID414323.1, genome: GCA_040096225.1), was isolated
from human faeces.

Description of *Lachnospira hominis* sp. nov.

Lachnospira hominis (ho'mi.nis. L. gen. masc. n. *hominis*, of a human being).

The genome size is 3.1 Mbp, G+C percentage is 41.75%, with 99.33% completeness
and 0.0% contamination. Strain CLA-AA-H89B was determined to represent a
separate species to its closest relative, *Lachnospira pectinoschiza* (97.48%), based
on 16S rRNA gene analysis. This was confirmed based on ANI comparison to all close
relatives which were below the species threshold. GTDB-Tk classification of strain
CLA-AA-H89B as 'Lachnospira sp000437735' confirmed that this isolate represents a
novel species. Functional analysis showed the strain has 112 transporters, 29

secretion genes, and predicted utilization of starch and cellulose, along with production of L-glutamate, folate, acetate, propionate, and riboflavin. Motility was predicted based on the presence of the following genes: *FlhA, FlhB, FlgB, FlgC, FlgD, FlgE, FlgF, FlgJ, FlgK, FlgL, FliC, FliD, FliE, FliF, FliG, FliK, FliM, FliN, MotA, MotB*. In total, 162 CAZymes were identified, with 21 different glycoside hydrolase families and 11 glycoside transferase families represented. The type strain, CLA-AA-H89B^T (phylum *Bacillota*, family *Lachnospiraceae*) (StrainInfo: 10.60712/SI-ID414325.1, genome: GCA_040095895.1), was isolated from human faeces.

Description of *Lachnospira intestinalis* sp. nov.

Lachnospira intestinalis (in.tes.ti.na'lis. N.L. fem. adj. *intestinalis*, pertaining to the intestines, from where the type strain was isolated).

The genome size is 3.15 Mbp, G+C percentage is 37.05%, with 98.66% completeness and 0.67% contamination. Strain CLA-JM-H10 was determined to represent a separate species to its closest relative, *Lachnospira rogosae* (96.37%), based on 16S rRNA gene analysis. This was confirmed by an ANI of 79.9% between *L. rogosa* (CLA-AA-H255), and strain CLA-JM-H10. GTDB-Tk classification of CLA-JM-H10 as 'Lachnospira sp900316325' confirmed that it represents a novel species. Functional analysis showed the strain has 109 transporters, 27 secretion genes, and predicted utilization of starch, and production of L-glutamate, folate, and cobalamin. Motility was predicted based on detection of the following genes: *FlhA, FlhB, FlgB, FlgC, FlgD, FlgE, FlgF, FlgJ, FlgK, FlgL, FliC, FliD, FliE, FliF, FliG, FliK, FliM, FliN, MotA, MotB*. This is consistent with the type species of this genus being motile. In total, 165 CAZymes were identified, with 22 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-JM-H10^T (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 114599) (StrainInfo: 10.60712/SI-ID414366.1, genome: GCA_040096395.1), was isolated from human faeces.

Description of *Lachnospira rogosae* sp. nov.

Lachnospira rogosae (ro.go'sae. N.L. gen. masc. n. *rogosae*, of Rogosa).

Strain CLA-AA-H255 was determined to be similar to *Lactobacillus rogosae* (99.87%) based on 16S rRNA gene analysis. However, the lack of a genome for the type strain of the latter species, along with the lack of the type strain at any established culture collection prevented further comparison (Tindall, 2014). GTDB-Tk classification of CLA-AA-H255 as 'Lachnospira rogosae_A' suggested that it represents a species within a genus distantly related to *Lactobacillus*. This was reconfirmed by the same placement of a second strain, CLA-AA-H191, which was also assigned to the same placeholder by GTDB-Tk (ANI of 98.86% between our two isolates). Based on these results, we propose *L. rogosae* was previously misassigned as a member of the genus *Lactobacillus*. To provide a type strain, and correct its placement, we propose the creation of the species *Lachnospira rogosae*. Functional analysis showed that strain

CLA-AA-H255 has 100 transporters, 25 secretion genes, and predicted utilization of
starch, and production of L-glutamate, folate, and riboflavin. The prediction of motility
and acetate production based on genomic analysis is consisting with the observed
phenotype of motility in the original type strain of *L. ragosae* as stated by Holdeman
and Moore (Holdeman and Moore, 1974). In total, 142 CAZymes were identified,
including 20 different glycoside hydrolase families and 12 glycoside transferase
families. Ecological analysis of 1,000 human gut 16S rRNA gene amplicon samples
identified this strain in 1.20% of samples with a relative abundance of 0.43 ± 0.78%.
The type strain, CLA-AA-H255^T (phylum *Bacillota*, family *Lachnospiraceae*)
(StrainInfo: 10.60712/SI-ID414300.1, genome: GCA_040096455.1), was isolated
from human faeces.

1049

Description of *Laedolimicola intestinihominis* sp. nov.

Laedolimicola intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, intestine; L.
masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human intestine).

The genome size is 3.45 Mbp, G+C percentage is 49.65%, with 99.37% completeness
and 0.16% contamination. It includes a single plasmid of 5,131 bp. Strain CLA-AA-
H132 was determined to represent a separate species to its closest relative,
Laedolimicola ammoniilytica (98.38%), based on 16S rRNA gene analysis. POCP
analysis confirmed that strain CLA-AA-H132 belongs to the recently named genus,
Laedolimicola, with a POCP value of 75.19% to the type strain of the only current
species within this genus, *L. ammoniilytica*. GTDDB-Tk placement as 'Merdisoma
sp900553635' suggests that *Laedolimicola* and *Candidatus* Merdisoma are
homonyms and require future reclassification. ANI comparison confirmed that CLA-
AA-H132 represents a novel species, as the ANI value to *L. ammoniilytica* was only
90.2%. Functional analysis showed the strain has 142 transporters, 21 secretion
genes, and predicted utilization of cellobiose, sucrose, starch, and production of
acetate, propionate, L-glutamate, cobalamin, and folate. In total, 153 CAZymes were
identified, with 21 different glycoside hydrolase families and 16 glycoside transferase
families represented. The type strain, CLA-AA-H132^T (phylum *Bacillota*, family
Lachnospiraceae) (=DSM 117481) (StrainInfo: 10.60712/SI-ID414271.1, genome:
GCA_040096155.1), was isolated from human faeces.

1070

Description of *Maccoya* gen. nov.

Maccoya (Mac.coy'a. N.L. fem. n. *Maccoya*, named after the immunologist Kathy
McCoy, for her many scientific contributions in the field of microbe-host interactions).

Based on 16S rRNA gene analysis, the closest species with a valid name are
Roseburia hominis (94.9%) and *Eubacterium oxidoreducens* (94.23%). POCP values
against all close relatives were below the genus delineation threshold of 50%,
including many *Roseburia* spp. (*R. hominis*, *R. faecis*, *R. porci*, *R. intestinalis*), apart
from *R. inulinivorans* (50.83%). GTDDB-Tk placement as "UBA11774 sp003507655"

confirmed that strain CLA-AA-H185 represents a novel genus within the family *Lachnospiraceae*. The type species is *Maccoya intestinihominis*.

Description of *Maccoya intestinihominis* sp. nov.

Maccoya intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, intestine; L. masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human intestine).

The genome size is 2.85 Mbp, G+C percentage is 41.17%, with 97.41% completeness and 0.45% contamination. It contains a single plasmid (2,341 bp). Functional analysis showed the strain has 99 transporters, 35 secretion genes, and predicted utilization of starch, and production of acetate, propionate, L-glutamate, cobalamin, folate, and riboflavin. In total, 110 CAZymes were identified, with 17 different glycoside hydrolase families and 13 glycoside transferase families represented. The type strain, CLA-AA-H185[T] (phylum *Bacillota*, family *Lachnospiraceae*) (StrainInfo: 10.60712/SI-ID414284.1, genome: GCA_040096355.1), was isolated from human faeces.

Description of *Megasphaera intestinihominis* sp. nov.

Megasphaera intestinihominis (in.tes.ti.ni.ho'mi.nis. L. gen. neut. n. *intestini*, of the intestine; L. gen. masc. n. *hominis*, of a human being; N.L. gen. masc. n. *intestinihominis*, of the human intestine).

The genome size is 2.38 Mbp, G+C percentage is 53.59%, with 100.00% completeness and 0.00% contamination. The closest relative to strain CLA-AA-H81 was *Megasphaera indica* (99.09%) based on 16S rRNA gene analysis. ANI comparison to all close relatives were below species assignment threshold (highest to *Megasphaera elsdenii,* 90.78%). GTDB-Tk classification as 'Megasphaera sp000417505' supports the creation of a novel species. Functional analysis showed the strain has 133 transporters, 16 secretion genes, and predicted utilization of starch, and production of butyrate, propionate, L-glutamate, folate, riboflavin, and cobalamin. Ecological analysis identified 152 matching (MASH distance < 0.05) MAGs, of which 124 originate from the human gut, suggesting this species is most commonly observed within this environment. This is supported by ecological analysis using 16S rRNA gene amplicon datasets which identified it within 19.0% of 1,000 human gut samples, with a relative abundance of 2.14 ± 5.23%. The type strain, CLA-AA-H81[T] (phylum *Bacillota*, family *Veillonellaceae*) (=DSM 118069) (StrainInfo: 10.60712/SI-ID414324.1, genome: GCA_040096415.1), was isolated from human faeces.

Description of *Niallia hominis* sp. nov.

Niallia hominis (ho'mi.nis. L. gen. n. *hominis*, of a human being).

The genome size is 4.9 Mbp, G+C percentage is 35.33%, with 92.24% completeness and 3.20% contamination. Strain CLA-SR-H024 was assigned to *Niallia circulans*

(100%) based on 16S rRNA gene analysis. However, ANI suggested the isolate
represents a novel species as comparison to all *Niallia* spp. were below 80%. GTDB-
Tk classification of strain CLA-SR-H024 as 'Niallia sp001076885' confirmed that it
represents a novel species. Functional analysis showed the strain has 244
transporters, 43 secretion genes, and predicted utilization of arbutin, salicin,
cellobiose, starch, and dextran, along with production of L-glutamate, folate, and
cobalamin. In total, 294 CAZymes were identified, with 34 different glycoside
hydrolase families and 14 glycoside transferase families represented. The type strain,
CLA-SR-H024[T] (phylum *Bacillota*, family *Bacillaceae*) (StrainInfo: 10.60712/SI-
ID414424.1, genome: GCA_040095995.1), was isolated from human faeces.

1128

Description of *Peptoniphilus hominis* sp. nov.

Peptoniphilus hominis (ho'mi.nis. L. gen. n. *hominis*, of a human being).

The genome size is 1.99 Mbp, G+C percentage is 33.8%, with 99.3% completeness
and 0.0% contamination. Strain CLA-SR-H025 was assigned to *Peptoniphilus*
gorbachii (99.11%) based on 16S rRNA gene analysis. However, ANI suggested the
isolate represents a novel species as comparison to *P. gorbachii* gave a value of
88.92%. GTDB-Tk classification of strain CLA-SR-H025 as 'Peptoniphilus_A
grossensis' confirmed that it represents a novel species, as the name 'Peptoniphilus
grossensis' was proposed but never validated [83]. Functional analysis showed the
strain has 12 transporters, 1 secretion genes, and no gut metabolic models were
identified within the genome. In total, 59 CAZymes were identified, with 10 different
glycoside hydrolase families and 8 glycoside transferase families represented. The
type strain, CLA-SR-H025[T] (phylum *Bacillota*, family *Peptoniphilaceae*) (Straininfo:
10.60712/SI-ID414425.1, genome: GCA_040096015.1), was isolated from human
faeces.

1144

Description of *Pseudoflavonifractor intestinihominis* sp. nov.

Pseudoflavonifractor intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*, the
intestine; L. masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the
human intestine).

The genome size is 3.69 Mbp, G+C percentage is 61.54%, with 99.33% completeness
and 0.00% contamination. Strain CLA-AP-H29 was assigned to the species
Pseudoflavonifractor capillosus (99.53%) based on 16S rRNA gene sequence
analysis. However, ANI suggested the isolate represents a novel species as
comparison to *P. capillosus* gave a value of 80.96%. GTDB-Tk classified strain CLA-
AP-H29 as 'Pseudoflavonifractor sp944387275', which confirms that it represents a
novel species. Functional analysis predicted the strain has 121 transporters, 14
secretion genes, and predicted utilization of starch, and production of L-glutamate,
folate, and cobalamin. In total, 180 CAZymes were identified, with 25 different
glycoside hydrolase families and 15 glycoside transferase families represented. The

type strain, CLA-AP-H29^T (phylum *Bacillota*, family *Oscillospiraceae*) (=DSM 801173) (Straininfo: 10.60712/SI-ID414342.1, genome: GCA_040096055.1), was isolated from human faeces.

Description of *Robertmurraya yapensis* sp. nov.

Robertmurraya yapensis (yap'ensis. N.L. masc./fem. adj. *yapensis*, pertaining to Yap trench, which is the geographical position where the first isolate of this species was obtained).

The genome size is 4.74 Mbp, G+C percentage is 37.94%, with 98.85% completeness and 2.13% contamination. It contains a plasmid (2,470 bp). The closest relative to strain CLA-AA-H227 was *Robertmurraya spiralis* (99.23%) based on 16S rRNA gene analysis. The highest POCP scores were to members of the genus *Robertmurraya* (*Robertmurraya kyonggiensis,* 84.9%; *R. spiralis,* 65.33%). The placement of strain CLA-AA-H227 within *Robertmurraya* was confirmed by GTDB-Tk assignment as 'Robertmurraya yapensis', a reclassification of the species 'Bacillus yapensis', although neither name has been validated. ANI comparison confirmed that CLA-AA-H227 represents a novel species, as values to close relatives were below the species level threshold. Functional analysis showed the strain has 246 transporters, 53 secretion genes, and predicted utilization of arbutin, salicin, cellobiose, starch, and production of butyrate, acetate, propionate, folate, riboflavin, and cobalamin. In total, 238 CAZymes were identified. The type strain, CLA-AA-H227^T (phylum *Bacillota*, family *Bacillaceae*) (=DSM 113004, =LMG 33018) (Straininfo: 10.60712/SI-ID414150.1, genome: GCA_040096375.1), was isolated from human faeces.

Description of *Ruminococcoides intestinale* sp. nov.

Ruminococcoides intestinale (in.tes.ti.na'le. N.L. neut. adj. *intestinalis*, pertaining to the intestines, from where the type strain was isolated).

The genome size is 2.32 Mbp, G+C percentage is 40.88%, with 99.33% completeness and 1.01% contamination. The isolate was determined to be similar to *Ruminococcus bromii* (98.91%) and more distantly related to *Ruminococcoides bili* (96.76%) based on 16S rRNA gene analysis. While POCP comparison of strain CLA-JM-H38 to *R. bromii* was 59.79%, and 53.56% to *Ruminococcus bovis,* suggesting they belong to the same genus, all other comparisons to *Ruminococcus* species were below 50%, including to the type species, *Ruminococcus flavefaciens* (27.58%). POCP to *R. bili*, the type species of the genus *Ruminococcoides*, was 64.44%. GTDB-Tk classified strain CLA-JM-H38 as "Ruminococcus_E bromii_B", confirming it is not a member of the genus *Ruminococcus.* These results support GTDB assignment that both *R. bovis* and *R. bromii* should be reclassified as members of the genus *Ruminococcoides.* Strain CLA-JM-H38 was confirmed to represent a novel species as all ANI comparisons to close relatives were below 95%, and it represents a distinct novel species from *Ruminococcoides intestinihominis* described in this work (78.33%).

Functional analysis showed the strain has 81 transporters, 15 secretion genes, and
predicted utilization of starch, and production of L-glutamate. In total, 108 CAZymes
were identified, with 15 different glycoside hydrolase families and 12 glycoside
transferase families represented. Ecological analysis based on 16S rRNA gene
amplicons identified this species in 55.20% of 1,000 human gut samples with a relative
abundance of 1.50 ± 2.49%, suggesting it is a prevalent and dominant bacterial
species within the human gut. The type strain, CLA-JM-H38^T (phylum *Bacillota*, family
Oscillospiraceae) (StrainInfo: 10.60712/SI-ID414376.1, genome:
GCA_040096305.1), was isolated from human faeces.

1209

Description of *Ruminococcoides intestinihominis* sp. nov.

Ruminococcoides intestinihominis (in.tes.ti.ni.ho'mi.nis. L. neut. n. *intestinum*,
intestine; L. masc. n. *homo*, a human being; N.L. gen. n. *intestinihominis*, of the human
intestine).

The genome size is 2.26 Mbp, G+C percentage is 34.26%, with 98.66% completeness
and 0.00% contamination. It contains one plasmid (1,825 bp). Based on 16S rRNA
gene sequence identity, the isolate was closely related to *Ruminococcus bovis*
(99.3%) and more distant to *Ruminococcoides bili* (94.8%), the type species of this
genus. ANI comparison confirmed the similarity of strain CLA-AA-H171 to *R. bovis*
(95.4%), however classification by GTDB-Tk as 'Ruminococcus_E sp934476515'
supported the creation of a novel species. Recently, 'Ruminococcus_E' has been
validly named as *Ruminococcoides*, with the type species *R. bili* [40]. POCP comparison
between the isolate and *R. bili* provided a value of 51.3%, suggesting that strain CLA-
AA-H171 represents a novel species within the genus *Ruminococcoides*. Functional
analysis showed the strain has 75 transporters, 14 secretion genes, and predicted
utilization of starch, and production of acetate. In total, 124 CAZymes were identified,
with 13 different glycoside hydrolase families and 12 glycoside transferase families
represented. Ecological analysis based on 16S rRNA gene amplicons identified this
species in 10.40% of 1,000 human gut samples with a relative abundance of 0.23 ±
0.68%. The type strain, CLA-AA-H171^T (phylum *Bacillota*, family *Oscillospiraceae*)
(=DSM 114689) (StrainInfo: 10.60712/SI-ID414279.1, genome: GCA_040096285.1),
was isolated from human faeces.

1232

Description of *Ruthenibacterium intestinale* sp. nov.

Ruthenibacterium intestinale (in.tes.ti.na'le. N.L. neut. adj. intestinale, pertaining to the
intestines, from where the type strain was isolated).

The genome size is 3.1 Mbp, G+C percentage is 54.69%, with 98.3% completeness
and 0.00% contamination. It contains a plasmid (5,063 bp). The closest relative to
strain CLA-JM-H11 is *Ruthenibacterium lactatiformans* (94.93%), the type species of
this genus, based on 16S rRNA gene analysis. Placement of the isolate within the
genus *Ruthenibacterium* was confirmed based on POCP comparison, with a value of

56.41% to the type species. Strain CLA-JM-H11 was confirmed to be distinct to *R.*
lactatiformans based on ANI comparison (79.28%). GTDB-Tk classification confirmed
this assignment as an unknown species within *Ruthenibacterium*. Functional analysis
showed the strain has 143 transporters, 16 secretion genes, and predicted utilization
of starch, and production of acetate, propionate, folate, and cobalamin. In total, 155
CAZymes were identified, with 27 different glycoside hydrolase families and 13
glycoside transferase families represented. The type strain, CLA-JM-H11^T (phylum
Bacillota, family *Oscillospiraceae*) (=DSM 114604, =LMG 33032) (StrainInfo:
10.60712/SI-ID414367.1, genome: GCA_040096265.1), was isolated from human
faeces.

1251

Description of *Sakamotonia* gen. nov.

Sakamotonia (Sa.ka.mo.to.ni'a. N.L. fem. n. *Sakamotonia*, named after the Japanese
microbiologist Mitsuo Sakamoto, for his many scientific contributions in the field of
bacterial taxonomy).

Based on 16S rRNA gene sequence identity, the closest relatives are members of the
genera *Clostridium* (*Clostridium indicum*, 94.0%) and *Lacrimispora* (*Lacrimispora*
amygdalina, 94.0%; *Lacrimispora sphenoides*, 93.01%). POCP analysis confirmed
that strain CLA-AA-H142 represents a distinct genus to *Clostridium* (*C. indicum*,
40.1%) and *Lacrimispora* (*L. sphenoides*, 37.2%) as all POCP values to close relatives
were below 50%. GTDB-Tk supported the creation of a novel genus within the family
Lachnospiraceae, placing strain CLA-AA-H142 within the proposed genus
"*Candidatus* Copromonas". However, as the name "Copromonas" is a homonym of an
existing genus, *Copromonas* (phylum: *Euglenozoa*) [84] within the Eukaryota, we have
named this genus *Sakamotonia*. The type species is *Sakamotonia hominis*.

1266

Description of *Sakamotonia hominis* sp. nov.

Sakamotonia hominis (ho'mi.nis. L. gen. masc. n. *hominis*, of a human being).

The genome size is 3.58 Mbp, G+C percentage is 48.07%, with 99.37% completeness
and 0.16% contamination. It includes a single plasmid of 5,504 bp. GTDB-Tk placed
CLA-AA-H142 within "*Candidatus* Copromonas" as "Copromonas sp900066535". This
placement was consistent with strain CLA-AA-H58, a second strain assigned to this
species (ANI of 97.4% between the two strains). Functional analysis showed that
strain CLA-AA-H142 has 129 transporters, 30 secretion genes, and predicted
utilization of starch, and production of acetate, propionate, L-glutamate, cobalamin,
folate, and riboflavin. In total, 119 CAZymes were identified, with 17 different glycoside
hydrolase families and 9 glycoside transferase families represented. The type strain,
CLA-AA-H142^T (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 111146)
(StrainInfo: 10.60712/SI-ID414272.1, genome: GCA_040096595.1), was isolated
from human faeces.

Description of *Solibaculum intestinale* sp. nov.

Solibaculum intestinale (in.tes.ti.na'le. N.L. neut. adj. intestinale, pertaining to the intestines, from where the type strain was isolated).

The genome size is 2.81 Mbp, G+C percentage is 54.62 %, with 97.99% completeness and 0.67% contamination. The isolate was determined to be a new species based on 16S rRNA gene analysis, with the closest validly named match being *Solibaculum mannosilyticum* (94.93%). Placement within *Solibaculum* was confirmed with POCP values above 50% to *S. mannosilyticum* (55.7%), the type species, and only member of this genus. ANI comparison confirmed the isolate represents a novel species, as no ANI values were above 80%. Functional analysis showed the strain has 82 transporters, 16 secretion genes, and predicted utilization of starch, and production of acetate, propionate, and L-glutamate. In total, 169 CAZymes were identified, with 20 different glycoside hydrolase families and 15 glycoside transferase families represented. The type strain, CLA-JM-H44^T (phylum *Bacillota*, family *Oscillospiraceae*) (=DSM 114601, =LMG 33034) (StrainInfo: 10.60712/SI-ID414377.1, genome: GCA_040096205.1), was isolated from human faeces.

Description of *Ventrimonas* gen. nov.

Ventrimonas (Ven.tri.mo'nas. L. masc. n. *venter*, the belly; L. fem. n. *monas*, a monad; N.L. fem. n. *Ventrimonas*, a microbe associated with faeces).

Based on 16S rRNA gene sequence identity, the closest relatives are members of the genus *Hungatella* (*Hungatella effluvii*, 95.15%; *Hungatella hathewayi*, 94.95%). POCP analysis against *H. effluvii* (40.38%) and *H. hathewayi* (39.86%) indicates that strain CLA-AP-H27 represents a distinct genus to *Hungatella*. GTDB-Tk supported the creation of a novel genus, placing strain CLA-AP-H27 within the proposed genus of "*Candidatus* Ventrimonas" in the family *Lachnospiraceae*. The type species of this genus is *Ventrimonas faecis*.

Description of *Ventrimonas faecis* sp. nov.

Ventrimonas faecis (fae'cis. L. gen. n. *faecis*, of dregs, pertaining to faeces, from where the type strain was isolated).

The genome size is 3.41 Mbp, G+C percentage is 49.27%, with 98.73% completeness and 0.63% contamination. Functional analysis showed the strain has 156 transporters, 21 secretion genes, and predicted utilization of starch, and production of acetate, propionate, L-glutamate, cobalamin, and folate. In total, 139 CAZymes were identified, with 21 different glycoside hydrolase families and 12 glycoside transferase families represented. The type strain, CLA-AP-H27^T (phylum *Bacillota*, family

Lachnospiraceae) (=DSM 118072) (StrainInfo: 10.60712/SI-ID414341.1, genome: GCA_040096075.1), was isolated from human faeces.

Description of *Waltera hominis* sp. nov.

Waltera hominis (ho'mi.nis. L. gen. masc. n. *hominis*, of a human being, pertaining to the human gut habitat, from where the type strain was isolated).

The genome size is 3.88 Mbp, G+C percentage is 45.72%, with 99.52% completeness and 2.13% contamination. The isolate was assigned to the species *Waltera intestinalis* (100.0%) based on 16S rRNA gene analysis. However, ANI comparison identified strain CLA-AA-H183 as a novel species within the genus *Waltera*, with an ANI value of 91.97% against the type species *Waltera intestinalis*. GTDB-Tk currently lacks the inclusion of *Waltera*, causing misclassification as 'Acetatifactor sp003447295', however this confirmed the proposition of a novel species. Separation of *Waltera* from *Acetatifactor* was revalidated via both phylogenomic analysis (**Supplementary Figure 8**), which shows both genera form separate monophyletic groups, and POCP analysis, which shows clear similarity within each genus (*Waltera*: 68.86%, *Acetatifactor*: 59.25%), and separation between the genera (39.94 ± 1.63 %). Functional analysis showed the strain has 141 transporters, 36 secretion genes, and predicted utilization of starch, cellulose, and production of butyrate, propionate, acetate, and folate. In total, 228 CAZymes were identified, with 38 different glycoside hydrolase families and 14 glycoside transferase families represented. The type strain, CLA-AA-H183^T (phylum *Bacillota*, family *Lachnospiraceae*) (=DSM 114684) (StrainInfo: 10.60712/SI-ID414283.1, genome: GCA_040096245.1), was isolated from human faeces.

Data availability

The genomes for all strains have been deposited at NCBI under BioProject: PRJNA996881. Bulk download of HiBC resources is possible via Zenodo for the genomes (https://doi.org/10.5281/zenodo.12180083), plasmid sequences (https://doi.org/10.5281/zenodo.12187897), 16S rRNA gene sequences (https://doi.org/10.5281/zenodo.12180259) and the isolates metadata (https://doi.org/10.5281/zenodo.12180506).

Acknowledgments

We are thankful to the NGS Competence Center Tübingen (NCCT) and the IZKF Core Facility Genomics at the University Hospital of RWTH Aachen for their support with genome sequencing. We thank Patrick Buchta from the Audio-Visual department from the University Hospital of RWTH Aachen for designing the HiBC logo, Marzena Wyschkon from the German Collection of Microorganisms and Cell Cultures for help with the deposition of strains, and Maurice Heizer for managing the HiBC at the University Hospital of RWTH Aachen. We are also grateful to Peter Vandamme,

Claudine Vereecke, and Anneleen Wieme for handling the submission of strains at the BCCM/LMG Bacteria Collection.

Funding

TCAH received funding from the German Research Foundation (DFG) as part of SFB1382 Gut-liver axis and from the RWTH Aachen START program, project "LeakyGut". TC received funding from the German Research Foundation (DFG): project no. 513892404; project no. 395357507 – SFB1371 Microbiome signatures, subproject Z01; project no. 403224013 – SFB1382 Gut-liver axis, subproject Q02; project no. 460129525 – NFDI4Microbiota. The data used in this publication was managed using the research data management platform Coscine with storage space granted by the Research Data Storage (RDS) of the DFG and Ministry of Culture and Science of the State of North Rhine-Westphalia (DFG: INST222/1261-1 and MKW: 214-4.06.05.08 - 139057).

Conflicts of interest

The authors have no conflicts of interest

References

1. Diakite, A. *et al.* Extensive culturomics of 8 healthy samples enhances metagenomics efficiency. *PLoS One* **14**, 1–12 (2019).

2. Forster, S. C. *et al.* A human gut bacterial genome and culture collection for improved metagenomic analyses. *Nat. Biotechnol.* **37**, 186–192 (2019).

3. Groussin, M. *et al.* Elevated rates of horizontal gene transfer in the industrialized human microbiome. *Cell* **184**, 2053-2067.e18 (2021).

4. Liu, C. *et al.* Enlightening the taxonomy darkness of human gut microbiomes with a cultured biobank. *Microbiome* **9**, 1–29 (2021).

5. Browne, H. P. *et al.* Culturing of 'unculturable' human microbiota reveals novel taxa and extensive sporulation. *Nature* **533**, 543–546 (2016).

6. Diop, K. *et al.* 'Lascolabacter vaginalis' strain KHD1, A new bacterial species cultivated from human female genital tract. *New Microbes New Infect.* **13**, 22–24 (2016).

7. Hedlund, B. P. *et al.* SeqCode: a nomenclatural code for prokaryotes described from sequence data. *Nat. Microbiol.* **7**, 1702–1708 (2022).

8. Göker, M., Moore, E. R. B., Oren, A. & Trujillo, M. E. Status of the SeqCode in the International Journal of Systematic and Evolutionary Microbiology. *Int. J. Syst. Evol. Microbiol.* **72**, 10–12 (2022).

9. Arahal, D. *et al.* The best of both worlds: a proposal for further integration of Candidatus names into the International Code of Nomenclature of Prokaryotes. *Int. J. Syst. Evol. Microbiol.* **74**, 1–21 (2024).

1399 10. Blanco-Míguez, A. *et al.* Extension of the Segatella copri complex to 13
1400   species with distinct large extrachromosomal elements and associations with
1401   host conditions. *Cell Host Microbe* **31**, 1804-1819.e9 (2023).

1402 11. De Filippis, F. *et al.* Distinct Genetic and Functional Traits of Human Intestinal
1403   Prevotella copri Strains Are Associated with Different Habitual Diets. *Cell Host*
1404   *Microbe* **25**, 444-453.e3 (2019).

1405 12. Fehlner-Peach, H. *et al.* Distinct Polysaccharide Utilization Profiles of Human
1406   Intestinal Prevotella copri Isolates. *Cell Host Microbe* **26**, 680-690.e5 (2019).

1407 13. Conteville, L. C. & Vicente, A. C. P. A plasmid network from the gut
1408   microbiome of semi-isolated human groups reveals unique and shared
1409   metabolic and virulence traits. *Sci. Rep.* **12**, 1–9 (2022).

1410 14. Fogarty, E. C. *et al.* Article A cryptic plasmid is among the most numerous
1411   genetic elements in the human gut ll ll Article A cryptic plasmid is among the
1412   most numerous genetic elements in the human gut. *Cell* **187**, 1206-1222.e16
1413   (2024).

1414 15. Yu, M. K., Fogarty, E. C. & Eren, A. M. Diverse plasmid systems and their
1415   ecology across human gut metagenomes revealed by PlasX and MobMess.
1416   *Nat. Microbiol.* **9**, 830–847 (2024).

1417 16. Perez, M. *et al.* A synthetic consortium of 100 gut commensals modulates the
1418   composition and function in a colon model of the microbiome of elderly
1419   subjects. *Gut Microbes* **13**, 1–19 (2021).

1420 17. Clark, R. L. *et al.* Design of synthetic human gut microbiome assembly and
1421   butyrate production. *Nat. Commun.* **12**, 1–16 (2021).

1422 18. Cheng, A. G. *et al.* Design, construction, and in vivo augmentation of a
1423   complex gut microbiome. *Cell* **185**, 3617-3636.e19 (2022).

1424 19. Derrien, M., Vaughan, E. E., Plugge, C. M. & de Vos, W. M. Akkermansia
1425   municiphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium.
1426   *Int. J. Syst. Evol. Microbiol.* **54**, 1469–1476 (2004).

1427 20. Plovier, H. *et al.* A purified membrane protein from Akkermansia muciniphila or
1428   the pasteurized bacterium improves metabolism in obese and diabetic mice.
1429   *Nat. Med.* **23**, 107–113 (2017).

1430 21. Overmann, J. Significance and future role of microbial resource centers. *Syst.*
1431   *Appl. Microbiol.* **38**, 258–265 (2015).

1432 22. Parker, C. T., Tindall, B. J. & Garrity, G. M. International code of nomenclature
1433   of Prokaryotes. *Int. J. Syst. Evol. Microbiol.* **69**, S1 (2019).

1434 23. Almeida, A. *et al.* A unified catalog of 204,938 reference genomes from the
1435   human gut microbiome. *Nat. Biotechnol.* (2020) doi:10.1038/s41587-020-0603-
1436   3.

1437 24. Seshadri, R. *et al.* Expanding the genomic encyclopedia of Actinobacteria with
1438   824 isolate reference genomes. *Cell Genomics* **2**, (2022).

1439 25. Segata, N., Börnigen, D., Morgan, X. C. & Huttenhower, C. PhyloPhlAn is a
1440   new method for improved phylogenetic and taxonomic placement of microbes.
1441   *Nat. Commun.* **4**, 1–10 (2013).

26. Jones, B. V, Sun, F. & Marchesi, J. R. Comparative metagenomic analysis of
plasmid encoded functions in the human gut microbiome. *BMC Genomics* **11**,
(2010).

27. Groussin, M. *et al.* Elevated rates of horizontal gene transfer in the
industrialized human microbiome. *Cell* **184**, 2053-2067.e18 (2021).

28. Rozov, R. *et al.* Recycler: An algorithm for detecting plasmids from de novo
assembly graphs. *Bioinformatics* **33**, 475–482 (2017).

29. Bankevich, A. *et al.* SPAdes: A new genome assembly algorithm and its
applications to single-cell sequencing. *J. Comput. Biol.* **19**, 455–477 (2012).

30. Pujol, C., Ehrlich, S. D. & Jannière, L. The promiscuous plasmids pIP501 and
pAMβ1 from gram-positive bacteria encode complementary resolution
functions. *Plasmid* vol. 31 100–105 (1994).

31. Schmartz, G. P. *et al.* PLSDB: Advancing a comprehensive database of
bacterial plasmids. *Nucleic Acids Res.* **50**, D273–D278 (2022).

32. Li, Y. *et al.* Distribution of megaplasmids in Lactobacillus salivarius and other
Lactobacilli. *J. Bacteriol.* **189**, 6128–6139 (2007).

33. Bottacini, F. *et al.* Discovery of a conjugative megaplasmid in Bifidobacterium
breve. *Appl. Environ. Microbiol.* **81**, 166–176 (2015).

34. García-Bayona, L., Coyne, M. J. & Comstock, L. E. Mobile Type VI secretion
system loci of the gut Bacteroidales display extensive intra-ecosystem transfer,
multi-species spread and geographical clustering. *PLoS Genet.* **17**, 1–25
(2021).

35. Riepe, S. P., Goldstein, J. & Alpers, D. H. Effect of secreted Bacteroides
proteases on human intestinal brush border hydrolases. *J. Clin. Invest.* **66**,
314–322 (1980).

36. Mills, R. H. *et al.* Multi-omics analyses of the ulcerative colitis gut microbiome
link Bacteroides vulgatus proteases with disease severity. *Nat. Microbiol.* 1–15
(2022) doi:10.1038/s41564-021-01050-3.

37. Pasolli, E. *et al.* Extensive Unexplored Human Microbiome Diversity Revealed
by Over 150,000 Genomes from Metagenomes Spanning Age, Geography,
and Lifestyle. *Cell* **176**, 649-662.e20 (2019).

38. Cruz, P., Mehretu, A. M., Buttner, M. P., Trice, T. & Howard, K. M.
Development of a polymerase chain reaction assay for the rapid detection of
the oral pathogenic bacterium , Selenomonas noxia. *BMC Oral Health* 1–8
(2015) doi:10.1186/s12903-015-0071-1.

39. Fodor, A. A. *et al.* The 'most wanted' taxa from the human microbiome for
whole genome sequencing. *PLoS One* **7**, (2012).

40. Molinero, N. *et al.* Ruminococcoides bili gen. Nov., sp. nov., a bile-resistant
bacterium from human bile with autolytic behavior. *Int. J. Syst. Evol. Microbiol.*
71, 1–11 (2021).

41. Guo, C. *et al.* Deficient butyrate-producing capacity in the gut microbiome is
associated with bacterial network disturbances and fatigue symptoms in
ME/CFS. *Cell Host Microbe* **31**, 288-304.e8 (2023).

42. Schmitz, M. A., Dimonaco, N. J., Clavel, T. & Hitch, T. C. A. Lineage-specific
microbial protein prediction enables large-scale exploration of protein ecology
within the human gut. *bioRxiv* (2024) doi:10.1101/2024.05.29.596415.

43. Ma, L. *et al.* Spermidine improves gut barrier integrity and gut microbiota
function in diet-induced obese mice. *Gut Microbes* **12**, 1–19 (2020).

44. Wiedmann, S., Eudy, J. D. & Zempleni, J. Biotin supplementation increases
expression of genes encoding interferon-γ, interleukin-1β, and 3-
methylcrotonyl-CoA carboxylase, and decreases expression of the gene
encoding interleukin-4 in human peripheral blood mononuclear cells. *J. Nutr.*
133, 716–719 (2003).

45. Agrawal, S., Agrawal, A. & Said, H. M. Biotin deficiency enhances the
inflammatory response of human dendritic cells. *Am. J. Physiol. - Cell Physiol.*
311, C386–C391 (2016).

46. Skupsky, J. *et al.* Biotin Supplementation Ameliorates Murine Colitis by
Preventing NF-κB Activation. *Cmgh* **9**, 557–567 (2020).

47. Mao, B. *et al.* Blautia producta displays potential probiotic properties against
dextran sulfate sodium-induced colitis in mice. *Food Sci. Hum. Wellness* **13**,
709–720 (2024).

48. van der Lelie, D. *et al.* Rationally designed bacterial consortia to treat chronic
immune-mediated colitis and restore intestinal homeostasis. *Nat. Commun.* **12**,
1–17 (2021).

49. Lee, C. *et al.* P926 Blautia Obeum Aggravates Colitis in a Murine Model. *J.*
Crohn's Colitis **17**, i1035–i1035 (2023).

50. Huang, T. Q. *et al.* Bergenin Alleviates Ulcerative Colitis By Decreasing Gut
Commensal Bacteroides vulgatus-Mediated Elevated Branched-Chain Amino
Acids. *J. Agric. Food Chem.* **72**, 3606–3621 (2024).

51. Sugihara, K. *et al.* Dietary phosphate exacerbates intestinal inflammation in
experimental colitis. *J. Clin. Biochem. Nutr.* **61**, 91–99 (2017).

52. Kolachala, V. L. *et al.* A2B Adenosine Receptor Gene Deletion Attenuates
Murine Colitis. *Gastroenterology* **135**, 861–870 (2008).

53. Sokol, H. *et al.* Faecalibacterium prausnitzii is an anti-inflammatory commensal
bacterium identified by gut microbiota analysis of Crohn disease patients.
Proc. Natl. Acad. Sci. U. S. A. **105**, 16731–16736 (2008).

54. Ueda, A. *et al.* Identification of Faecalibacterium prausnitzii strains for gut
microbiome-based intervention in Alzheimer's-type dementia. *Cell Reports*
Med. **2**, 100398 (2021).

55. D'hoe, K. *et al.* Integrated culturing, modeling and transcriptomics uncovers
complex interactions and emergent behavior in a three-species synthetic gut
community. *Elife* **7**, 1–30 (2018).

56. Fitzgerald, C. B. *et al.* Comparative analysis of Faecalibacterium prausnitzii
genomes shows a high level of genome plasticity and warrants separation into
new species-level taxa. *BMC Genomics* **19**, 1–20 (2018).

57. Vital, M., Karch, A. & Pieper, D. H. Colonic Butyrate-Producing Communities in
Humans : an Overview Using Omics Data. *mSystems* **2**, 1–18 (2017).

58.   Afrizal, A. *et al.* Enhanced cultured diversity of the mouse gut microbiota
1530   enables custom-made synthetic communities. *Cell Host Microbe* 1–16 (2022)
1531   doi:10.1016/j.chom.2022.09.011.

1532   59.   Wylensek, D. *et al.* A collection of bacterial isolates from the pig intestine
1533   reveals functional and taxonomic diversity. *Nat. Commun.* **in press**, 1–26
1534   (2020).

1535   60.   Stackebrandt, E. *et al.* Deposit of microbial strains in public service collections
1536   as part of the publication process to underpin good practice in science.
1537   *Springerplus* **3**, 1–4 (2014).

1538   61.   Burz, S. D. *et al.* A Guide for Ex Vivo Handling and Storage of Stool Samples
1539   Intended for Fecal Microbiota Transplantation. *Sci. Rep.* **9**, 1–16 (2019).

1540   62.   Afrizal, A. *et al.* Anaerobic single-cell dispensing facilitates the cultivation of
1541   human gut bacteria. *Environ. Microbiol.* **00**, (2022).

1542   63.   Godon, J. J., Zumstein, E., Dabert, P., Habouzit, F. & Moletta, R. Molecular
1543   microbial diversity of an anaerobic digestor as determined by small-subunit
1544   rDNA sequence analysis. *Appl. Environ. Microbiol.* **63**, 2802–2813 (1997).

1545   64.   Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for
1546   Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

1547   65.   Bushnell, B. BBMap: A Fast, Accurate, Splice-Aware Aligner. in *9th Annual
1548   Genomics of Energy & Environment Meeting* (2014).

1549   66.   Antipov, D. *et al.* PlasmidSPAdes: Assembling plasmids from whole genome
1550   sequencing data. *Bioinformatics* **32**, 3380–3387 (2016).

1551   67.   Yilmaz, P. *et al.* Minimum information about a marker gene sequence
1552   (MIMARKS) and minimum information about any (x) sequence (MIxS)
1553   specifications. *Nat. Biotechnol.* **29**, 415–420 (2011).

1554   68.   Parks, D. H., Imelfort, M., Skennerton, C. T., Hugenholtz, P. & Tyson, G. W.
1555   CheckM: assessing the quality of microbial genomes recovered from. *Cold
1556   Spring Harb. Lab. Press Method* **1**, 1–31 (2015).

1557   69.   Mikheenko, A., Prjibelski, A., Saveliev, V., Antipov, D. & Gurevich, A. Versatile
1558   genome assembly evaluation with QUAST-LG. *Bioinformatics* **34**, i142–i150
1559   (2018).

1560   70.   Bengtsson-Palme, J. *et al.* metaxa2: Improved identification and taxonomic
1561   classification of small and large subunit rRNA in metagenomic data. *Mol. Ecol.
1562   Resour.* **15**, 1403–1414 (2015).

1563   71.   Schwengers, O. *et al.* Bakta: Rapid and standardized annotation of bacterial
1564   genomes via alignment-free sequence identification. *Microb. Genomics* **7**,
1565   (2021).

1566   72.   Mölder, F. *et al.* Sustainable data analysis with Snakemake [version 2; peer
1567   review: 2 approved]. *F1000Research* **10**, 1–29 (2021).

1568   73.   Hitch, T. C. A. *et al.* Automated analysis of genomic sequences facilitates high-
1569   throughput and comprehensive description of bacteria. *ISME Commun.* **1**,
1570   (2021).

74.   Asnicar, F. *et al.* Precise phylogenetic analysis of microbial isolates and

genomes from metagenomes using PhyloPhlAn 3.0. *Nat. Commun.* **11**, 1–10
(2020).

75.   Hyatt, D. *et al.* Prodigal: prokaryotic gene recognition and translation initiation
site identification. *BMC Bioinformatics* **11**, 119 (2010).

76.   Aramaki, T. *et al.* KofamKOALA: KEGG Ortholog assignment based on profile
HMM and adaptive score threshold. *Bioinformatics* **36**, 2251–2252 (2020).

77.   Shannon, P. *et al.* Cytoscape: a software environment for integrated models of
biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).

78.   Beverley, S. M. Estimation of circular DNA size using γ-irradiation and pulsed-
field gel electrophoresis. *Anal. Biochem.* **177**, 110–114 (1989).

79.   Yarza, P. *et al.* Uniting the classification of cultured and uncultured bacteria
and archaea using 16S rRNA gene sequences. *Nat. Rev. Microbiol.* **12**, 635–
645 (2014).

80.   Jain, C., Rodriguez-R, L. M., Phillippy, A. M., Konstantinidis, K. T. & Aluru, S.
High throughput ANI analysis of 90K prokaryotic genomes reveals clear
species boundaries. *Nat. Commun.* **9**, 5114 (2018).

81.   Qin, Q. L. *et al.* A proposed genus boundary for the prokaryotes based on
genomic insights. *J. Bacteriol.* **196**, 2210–2215 (2014).

82.   Meile, L., Rohr, L. M., Geissmann, T. A., Herensperger, M. & Teuber, M.
Characterization of the D-xylulose 5-phosphate/D-fructose 6-phosphate
phosphoketolase gene (xfp) from Bifidobacterium lactis. *J. Bacteriol.* **183**,
2929–2936 (2001).

83.   Mishra, A. K., Hugon, P., Robert, C., Raoult, D. & Fournier, P. E. Non
contiguous-finished genome sequence and description of Peptoniphilus
grossensis sp. nov. *Stand. Genomic Sci.* **7**, 320–330 (2012).

84.   Dobell, C. C. The Structure and Life-History of Copromonas subtilis, nov. gen.
et nov. spec.: a Contribution to our Knowledge of the Flagellata. *J. Cell Sci.*
S2-**52**, 75–120 (1908).

1600

1601

Supplementary Tables

Supplementary Table 1: Statistical comparison of genome sizes of phyla present within the HiBC, UHGG (isolates), and complete UHGG.

Supplementary Table 2: Statistical comparison of the normalised carbohydrate active enzyme investment of phyla within the HiBC.

Supplementary Table 3: HPLC measurement of the production and/or utilisation of multiple metabolites.

Genome size (Mbp)

Completeness (%)
Contamination (%)

Tree scale: 0.1

● **Novel taxa**

Contamination (%)

0   5

Completeness (%)

90   100

Phyla

● Bacteroidota
● Pseudomonadota
● Bacillota
● Actinomycetota
● Desulfobacterota
● Verrucomicrobiota
● Fusobacteriota

Isolation

Description

Current strategies

→ 1. Publication

→ 2. Publication, then deposition*

→ 3. Parallelled publication & deposition*

→ 4. Deposition*, then publication

*Single strain deposition

1, Only original strain ID in publication
2, Strain may fail to be deposited
3, Deposition is time consuming

Proposed system

Curated (meta)data — 1. Unique identifier (doi) →

Pure Strains — 2. BULK submission →

Iterative strain processing

Supplementary Figure 1. a. The genome size of each HiBC strain (n = 340) was calculated in mega base pairs (Mbp). **b.** Genome size of all isolates (n = 891) within the UHGG collection. **c.** The genome size of all genomes (isolates and MAGs) within the UHGG collection (Almeida *et al*, 2021) (n = 4614). Black dots represent the mean value for each group. Statistical comparison of all groups is provided in Supplementary Table 1.

Supplementary Figure 2. a. Frequency of each gut metabolic modules detection across the 340 HiBC strains. Modules are coloured according to their broad functional assignments. **b.** Comparison of each strains CAZyme repertoire compared to its coding potential (total number of coding sequences), coloured based on phyla. **c.** The CAZyme repertoire of each strain normalised to their total coding potential, grouped by phyla. Black dots represent the mean value for each group. **d-f.** The functional investment of strains belonging to each phyla into the production of acetate, butyrate, and propionate.

Supplementary Figure 3. a. The impact plasmids of specific sizes should theortically have on ANI comparison between two genomes of a set size was calculated and is stated in this matrix. In green are values less than 1%, when a plasmid has a >1% impact on ANI comparison, it is shown in orange. **b.** Comparison of each HiBC strain to its closest assignment, via GTDB-Tk, was calculated with and without plasmids (strains = 152). The presence of plasmids within the genomes significantly reduced the ANI score to the closest relatives, although the impact on ANI was 0.004 ± 0.01 and never altered the taxonomic assignment of a strain.

Supplementary Figure X. a. Network visualisation of plasmid sequence similarity. Plasmids (circles) with similar sequences are connected with edges, the distance of which is proportional to their similarity (shorter = similar; longer = dissimilar). Plasmids are coloured based on their phyla and their size is proportional to the number of matching plasmids within PLSDB. Plasmids / Clusters of interest are named (underlined for known) and highlighted; grey for known, brown for novel. **b.** Country occurrence of the pBAC plasmid. **c.** Country occurrence of the pMMCAT_H253 plasmid. **d.** Mobmess network comparison of sequence similarity between pMMCAT_H253 matches within PLSDB. Each node represents a plasmid sequence, coloured based on the taxonomy of their originating isolate. The length of edges between nodes is based on the pairwise ANI comparison of plasmids. **e.** Detection of pMMCAT_H253 across 1,782 metagenomes, grouped based on their country of origin. Detection is defined as the proportion of nucletodies within the pMMCAT reference sequence covered by atleast one read within the studied sample.

Supplementary Figure 8. Analysis of the prevalence of each HBC strain (labelled used their strain identifier) within 1,000 16S rRNA gene amplicon samples from the gut, vagina, lung, and skin. The heatmap indicates the prevalence at which the strain was identified within the ecosystem being studied. On the left, the phyla level assignment of each strain is indicated based on the defined colour scheme.

Supplementary Figure 6. Phylogenomic diversity of the eight novel species identified to be on the Human Microbiome Projects (HMP) most wanted listed. The inner ring is coloured according to the phyla assignment of the species, which are all *Bacillota*. The outer ring indicates the priority of each species in the most wanted list.

Supplementary Figure 7. a. Consistency between predicted short chain fatty acid production and experimental results were tested by studying 23 strains. Black boxes indicate the presence of a GMM for production of the SCFA of interest. Boxes marked with an asterik within the experimental data (Exp.) indicates values below the detection limit, or with high noise to signal ratio. **b.** Annotation of each HiBC strain for the KOs within the acetyl-CoA pathway for butyrate production.

Supplementary Figure 8. Phylogenomic tree of both validly named *Acetatifactor*, and the only currently validly named *Waltera* species, with the proposed *Waltera hominis*. The type species for both *Kineothrix* and *Lacrimispora* are also included to provide greater context. The tree is rooted on the outgroup of *Lachnospira multipara*.